ModernaTX, Inc.  
mRNA -1345 -P304  Protocol  mRNA -1345  
Confidential  Page 1  
CLINICAL STUDY PROTO COL   
Protocol Title:  A Phase 3, Randomized, Observer -blind Study to Evaluate Safety, 
Tolerability, and Immunogenicity of mRNA -1345, an mRNA Vaccine 
Targeting Respi[INVESTIGATOR_14250], When Coadministered With a 
High -dose, Quadrivalent Seasonal Influenza Vaccine in Adults ≥65 Years 
of Age  
Protocol Number:  mRNA -1345 -P304 
Date:  11 JUL 2023  
Compound:  mRNA -1345  
Brief Title:  A Study to Investigate the Safety and Immune Response of mRNA -1345, 
an mRNA Vaccine Targeting RSV, When Coadministered With a 
High -dose, Quadrivalent Seasonal Influenza Vaccine in Adults ≥65 Years 
of Age  
Study Phase:  3 
Sponsor Name:  [CONTACT_14358], Inc.  
Legal Registered 
Address:  200 Technology Square  
Cambridge, MA 0213 9 
Regulatory Agency 
Identifier Number:  Registry : 
IND ID: 
[ZIP_CODE]  
Sponsor Signatory:  
See e -Signature [CONTACT_14359].  
Sponsor Signatory  and Contact [CONTACT_9249] . 
 
CONFIDENTIAL  
This document contains confidential information, which should not be copi[INVESTIGATOR_530], referred to, released, or 
published to anyone without written approval from ModernaTX, Inc.  
 
  
[STUDY_ID_REMOVED]
ModernaTX, Inc.  
mRNA -[ADDRESS_13568] read and understood all sections of the protocol entitled “ A Phase 3, Randomized, 
Observer -blind Study to Evaluate Safety, Tolerability, and I mmunogenicity of mRN A-1345, an 
mRNA Vaccine Targeting Respi[INVESTIGATOR_14250], When Coadministered  With a 
High -dose, Quadrivalent Seasonal Influenza Vaccine in Adults ≥65 Years of Age ” dated 
[ADDRESS_13569] the clinical investigation in 
accordance with the current Protocol, the International Council for Harmonisation (ICH) of 
Technical Requirements for Registration of Pharmaceuticals for Human Us e, E6(R2) Good 
Clinical Practice (GCP) Guidance , and all applicable local and country regulations. I will not 
make changes to the protocol before consulting with ModernaTX, Inc. or implement protocol 
changes without IRB/IEC approval except to eliminate an immediate risk to participants.  
I agree to administer study treatment only to participants under my personal supervision or the 
supervision of a Subinvestigator . I will not supply study treatment to any person not authorized 
to receive it. I also agree tha t persons debarred from conducting or working on clinical studies by 
[CONTACT_14292] a partnership in which the Sponsor is involved. I will immediately disclose it in writi ng to the 
Sponsor if any person who is involved in the study is debarred, or if any proceeding for 
debarment is pending, or, to the best of my knowledge, threatened.  
I will not disclose confidential information contained in this document including particip ant 
information, to anyone other than the recipi[INVESTIGATOR_14251]/IEC. I agree 
to ensure that this information will not be used for any purpose other than the evaluation or 
conduct of the clinical investigation without the prior writte n consent from ModernaTX, Inc. I 
will not disclose information regarding this clinical investigation or publish results of the 
investigation without authorization from ModernaTX, Inc.  
The signature [CONTACT_14360] l be conducted 
according to all stipulations of the protocol, including statements regarding confidentiality, and 
according to local legal and regulatory requirements, regulations, and ICH E6(R2) GCP 
guidelines . 
 
Signature [CONTACT_789]    [INVESTIGATOR_14252], Inc.  
mRNA -[ADDRESS_13570] OF ABBREVIATION S ................................ ................................ ................................ .......... 8 
1. PROTOCOL SUMMARY  ................................ ................................ .......................... 11 
1.1. Protocol Synopsis  ................................ ................................ ................................ .......11 
1.2. Schema  ................................ ................................ ................................ ........................ 14 
1.3. Schedule of Activities  ................................ ................................ ................................ .15 
2. INTRODUCTION  ................................ ................................ ................................ ......18 
2.1. Study Rationale  ................................ ................................ ................................ ........... 19 
2.2. Background  ................................ ................................ ................................ ................. 19 
2.3. Benefit/Risk Assessment  ................................ ................................ ............................ 20 
2.3.1.  Risk Assessment  ................................ ................................ ................................ ......... 20 
2.3.2.  Benefit Assessment  ................................ ................................ ................................ .....20 
2.3.3. Overall Benefit/Risk Conclusion  ................................ ................................ ................ 21 
3. OBJECTIVES AND ENDPO INTS  ................................ ................................ ............ 22 
4. STUDY DESIGN  ................................ ................................ ................................ .......24 
4.1. Overall  Design  ................................ ................................ ................................ ............ 24 
4.2. Scientific Rationale for Study Design  ................................ ................................ ........ 24 
4.3. End of Study Definition  ................................ ................................ .............................. 25 
5. STUDY POPULATION  ................................ ................................ ............................. 26 
5.1. Inclusion Criteria  ................................ ................................ ................................ ........ 26 
5.2. Exclusion Criteria  ................................ ................................ ................................ .......26 
5.3. Screen Failures  ................................ ................................ ................................ ............ 29 
5.4. Criteria for Temporarily Delaying the Administration of Study Intervention  ........... 29 
6. STUDY INTERVENTIONS AND CONCOMITANT THER APY ........................... 30 
6.1. Study Interventions Administered  ................................ ................................ .............. 30 
6.2. Preparation, Handling, Storage, and Accountability  ................................ .................. 31 
6.3. Assignment to Study Intervention  ................................ ................................ .............. 31 
6.4. Blinding  ................................ ................................ ................................ ...................... 31 
6.4.1.  Unblinding  ................................ ................................ ................................ .................. 32 
6.5. Study Intervention Compliance  ................................ ................................ .................. 32 
ModernaTX, Inc.  
mRNA -1345 -P304  Protocol  mRNA -1345  
Confidential  Page 4 6.6. Dose Modification  ................................ ................................ ................................ ......33 
6.7. Continued Access to Study Intervention After the End of the Study  ......................... 33 
6.8. Treatment of Overdose  ................................ ................................ ............................... 33 
6.9. Prior and Concomitant Therapy  ................................ ................................ .................. 33 
6.9.1.  Prohibited Therapy  ................................ ................................ ................................ .....33 
6.9.2. Concomitant Medications, Therapi[INVESTIGATOR_014], and Procedures  ................................ ............... 34 
6.9.3.  Concomitant Medications and Vaccines That May Lead to the Elimi nation 
of a Participant from the Per Protocol Analyses  ................................ ......................... 34 
7. DISCONTINUATION OF S TUDY INTERVENTION AN D 
PARTICIPANT DISCONTI NUATION/WITHDRAWAL  ................................ .......36 
7.1. Discontinuation of Study Intervention ................................ ................................ ........ 36 
7.2. Participant Discontinuation/Withdrawal from the Study  ................................ ........... [ADDRESS_13571]  ................................ ................................ ............. 45 
[IP_ADDRESS].  Anaphylaxis  ................................ ................................ ................................ ................ 46 
[IP_ADDRESS].  Myocarditis and/or Pericarditis  ................................ ................................ ................... 46 
8.5. Pharmacokinetics  ................................ ................................ ................................ ........ 46 
ModernaTX, Inc.  
mRNA -1345 -P304  Protocol  mRNA -1345  
Confidential  Page 5 8.6. Pharmacodynamics  ................................ ................................ ................................ .....46 
8.7. Biomarkers  ................................ ................................ ................................ .................. 47 
9. STATISTIC AL CONSIDERATIONS  ................................ ................................ .......48 
9.1. Blinding and Responsibility for Analyses  ................................ ................................ ..48 
9.2. Statistical Hypothesis  ................................ ................................ ................................ ..48 
9.3. Sample Size Determination  ................................ ................................ ........................ 50 
9.4. Analysis Sets  ................................ ................................ ................................ ............... 51 
9.5. Statistical Analyses  ................................ ................................ ................................ .....52 
9.5.1. Immunogenicity Analyses  ................................ ................................ .......................... 52 
9.5.2.  Safety Analyses  ................................ ................................ ................................ .......... 53 
9.5.3.  Exploratory Analyses (May Be Performed)  ................................ ............................... 54 
9.6. Planned Analyses  ................................ ................................ ................................ ........ 54 
9.6.1.  Primary Analysis  ................................ ................................ ................................ ........ 54 
9.6.2.  Final Analysis  ................................ ................................ ................................ ............. 54 
9.6.3.  Multiplicity  ................................ ................................ ................................ ................. 54 
10. SUPPORTING DOCUMENTA TION AND OPERATIONAL  
CONSIDERATIONS  ................................ ................................ ................................ ..55 
10.1.  Appendix  1: Regulatory, Ethical, and Study Oversight Considerations  .................... 55 
10.1.1.  Regulatory and Ethical Considerations  ................................ ................................ ......55 
10.1.2.  Financial Disclosure  ................................ ................................ ................................ ...55 
10.1.3.  Informed Consent Process  ................................ ................................ .......................... 56 
10.1.4.  Recruitment Strategy  ................................ ................................ ................................ ..56 
10.1.5.  Data Protection  ................................ ................................ ................................ ........... 56 
10.1.6. Committees Structure  ................................ ................................ ................................ .57 
[IP_ADDRESS].  Internal Safety Team  ................................ ................................ ................................ ...57 
[IP_ADDRESS].  Cardiac Event Adjudication Committee  ................................ ................................ .....57 
10.1.7.  Dissemination of Clinical Study Data  ................................ ................................ ........ 57 
10.1.8.  Data Quality Assurance  ................................ ................................ .............................. 57 
10.1.9.  Source Documents  ................................ ................................ ................................ ......58 
10.1.10.  Study and Site Start and Closure  ................................ ................................ ................ 59 
10.1.11.  Publication Policy  ................................ ................................ ................................ .......59 
10.2.  Appendix  2: AEs and SAEs: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting  ................................ ................................ ........ 61 
ModernaTX, Inc.  
mRNA -1345 -P304  Protocol  mRNA -1345  
Confidential  Page 6 10.2.1.  Definiti on of AE  ................................ ................................ ................................ ......... 61 
10.2.2.  Definition of SAE  ................................ ................................ ................................ .......62 
10.2.3.  Definition of MAAE  ................................ ................................ ................................ ...63 
10.2.4.  Definition of AESI  ................................ ................................ ................................ ......63 
10.2.5.  Recording and Follow -Up of AE and/or SAE  ................................ ............................ 63 
10.2.6.  Reporting of SAEs  ................................ ................................ ................................ ......67 
10.3.  Appendix  3: Adverse Events of Special Interest  ................................ ........................ 67 
10.3.1.  AESIs  ................................ ................................ ................................ .......................... 67 
10.4.  Appendix  4: CDC Working Case Definitions of Pericarditis, Myocarditis, 
and Myopericarditis After Receipt of COVID -[ADDRESS_13572] OF TABLES   
Table  1: Schedule of Activities  ................................ ................................ ................................ .15 
Table  2: Objectives and Endpoints  ................................ ................................ ........................... 22 
Table  3: Study Interventions Administered  ................................ ................................ .............. 30 
Table  4: Study Arms and Dosing Regimens  ................................ ................................ ............. 31 
Table  5: Sample Size Justification  ................................ ................................ ............................ 51 
Table  6: Analysis Sets  ................................ ................................ ................................ ............... 51 
Table  7: Adult and Adolescent Solicited Adverse Reactions and Grades  ................................ 64 
Table  8: Adverse Events of Special Interest  ................................ ................................ ............. 67 
Table  9: Case Definitions of Probably and Confirmed Myocarditis, Pericarditis, and 
Myopericarditis After Receipt of COVID -[ADDRESS_13573] OF FIGURES   
Figure  1: Study Schema  ................................ ................................ ................................ ............. [ADDRESS_13574]  
AR Adverse reaction  
bAb Binding antibody  
CD Clusters of differentiation  
CDC  Centers for Disease Control and Prevention  
CEAC  Cardiac Event Adjudication Committee  
cMRI  Cardiac magnetic resonance imaging  
COVID -19 Coronavirus disease 2019  
CRF  Case report form  
CSR  Clinical study report  
ECG (or  EKG)  Electrocardiogram  
eCRF  Electronic case report form  
EDC  Electronic data collection  
eDiary  Electronic Diary  
EoS End of study  
FAS Full analysis set  
FluSurv -NET  Influenza Hospi[INVESTIGATOR_14253], Inc.  
mRNA -1345 -P304  Protocol  mRNA -1345  
Confidential  Page 9 Abbreviation  Definition  
HELLP  Hemolysis, elevated liver enzymes, and low platelet count  
IB Investigator’s brochure  
ICF Informed consent form  
ICH International Conference on Harmonisation  
IEC Independent Ethics Committee  
Ig Immunoglobulin  
IM Intramuscular  
IRB Institutional Review Board  
IST Internal safety team  
IVRS  Interactive voice  response system  
IWRS  Interactive web response system  
LB Lower bound  
LLOQ  Lower limit of quantification  
LNP  Lipid nanoparticle  
LRTD  Lower respi[INVESTIGATOR_14254] -the-counter  
PP Per protocol  
QTL  Quality tolerance limit  
RSV  Respi[INVESTIGATOR_14255], Inc.  
mRNA -1345 -P304  Protocol  mRNA -1345  
Confidential  Page 10 Abbreviation  Definition  
SoA Schedule of Activities  
SRR  Seroresponse rate  
ULOQ  Upper limit of quantification  
USV  Unscheduled visit  
V In-person visit  
WHO  World Health Organization  
 
ModernaTX, Inc.  
mRNA -1345 -P304  Protocol  mRNA -1345  
Confidential  Page 11 1. PROTOCOL SUMMARY   
1.1. Protocol Synopsis   
Protocol Title:  
A Phase 3, Randomized, Observer -blind Study to Evaluate Safety, Tolerability, and 
Immunogenicity of mRN A-1345, an mRNA Vaccine Targeting Respi[INVESTIGATOR_14250], 
When Coadministered  With a High -dose, Quadrivalent Seasonal Influenza Vaccine in Adults 
≥65 Years of Age  
Brief  Title:  
A Study to Investigate the Safety and Immune Response of mRN A-1345, an mRNA Vaccine 
Targeting RSV, When Coadministered With a High -dose, Quadrivalent Seasonal Influenza 
Vaccine in Adults ≥65 Years of Age  
Regulatory Agency Identifier Number(s):  
Registry  ID 
IND [ZIP_CODE]  
Rationale : 
The Sponsor’s position is that the co administration  of mRN A-1345 with a seasonal influenza 
vaccine will allow people to receive both vaccines at once to reduce the number of visits and add 
to the uptake/convenience in people at risk for both RSV and influenza diseases.  
Objectives  and Endpoint s: 
Objectives  Endpoints  
Primary   
• To evaluate the safety and reactogenicity of 
mRN A-1345 RSV vaccine coadministered  
with a HD quadrivalent seasonal influenza 
vaccine (Fluzone® HD). • Solicited local and systemic ARs through 
7 days after each injection . 
• Unsolicited AEs through 21 days after each 
study injection . 
• MAAEs from Day [ADDRESS_13575] 
study injection /EoS . 
• AESI from Day [ADDRESS_13576] study 
injection /EoS. 
• SAEs from Day [ADDRESS_13577] study 
injection /EoS. 
• AEs leading to discontinuation from Day [ADDRESS_13578] study injection /EoS. 
• To evaluate the impact of coadministered  HD 
quadrivalent seasonal influenza vaccine on the 
immune response to mRN A-[ADDRESS_13579] RS V-A and RS V-B. • GMT of serum RS V-A and RS V-B nAbs at 
Day 22 (Arm 1 a) or Day 43 (Arm 2 b). 
ModernaTX, Inc.  
mRNA -1345 -P304  Protocol  mRNA -1345  
Confidential  Page 12 Objectives  Endpoints  
• To evaluate the impact of coadministered  
mRN A-[ADDRESS_13580] 4  vaccine -matched 
influenza A and B strains . • GMT of serum anti-HA Ab level as measured 
by [CONTACT_14293]  22. 
Secondary   
• To further evaluate the effect of mRN A-1345 
RSV vaccine coad ministered with a HD 
quadrivalent seasonal influenza vaccine on the 
immune response to RS V-A and RS V-B. • SRRc for RSV-A and RS V-B nAbs at Day  22 
(Arm 1) or Day 43 (Arm 2). 
• GMFR of postinjection RS V-A and RS V-B 
nAbs (Day  22 for Arm 1 and Day  43 for 
Arm 2) compared to baseline  (Day  1 for 
Arm 1 and Day  22 for Arm 2). 
• Proportion of participant s with ≥2 -fold 
increase  in RSV -A and RSV -B nAb s at 
Day 22 (Arm 1) or Day  43 (Arm 2).  
• To further evaluate the effect of mRN A-[ADDRESS_13581] 4  vaccine -matched 
influenza A and B strains . • SCRd at Day 22 as measured by [CONTACT_14294] . 
• GMFR comparing Day 1 (baseline ) and 
Day 22 measured by [CONTACT_14295] . 
Exploratory (may be performed)   
• To further evaluate the immune response 
across study vaccines . • GMC and GMFR of postinjection/ baseline 
titers of RSV bAbs. 
• Proportion of participants with ≥2 -fold and 
≥4-fold increases in RS V bAb concentration 
postinjection.  
• Frequency, specificities, or other endpoints to 
be determined, for the further 
characterization of immune responses . 
 
Abbreviations: Ab = antibody; AE = adverse event; AESI  = adverse event of special interest; AR  = adverse reaction; 
bAb = binding antibody; EoS = end of study; GMC  = geometric mean concentration; GMFR  = geometric mean 
fold rise; GMT  = geometric mean titer; HAI  = hemagglutination inhibition; HD  = high dose; LLOQ  = lower limit 
of quantification; MAAE  = medically attended adverse event ; nAb = neutralizing antibody; RSV  = respi[INVESTIGATOR_14256]; SAE  = serious adverse event ; SCR  = seroconversion rate; SRR  = seroresponse rate . 
a. Arm 1: Fluzone HD +mRN A-1345  μg on Day 1 followed by [CONTACT_14296] (0.9 % sodium chloride ) on Day 22. 
b. Arm 2: Fluzone HD +placebo (0.9 % sodium chloride) on Day 1 followed by [CONTACT_14297] A-1345  μg on Day 22. 
c. Seroresponse is defined as postvaccination titers  ≥4×LLOQ if baseline is <LLOQ or a ≥4-fold increase from  
baseline if baseline is ≥LLOQ.  
d. Seroconversion is defined as postvaccination titer ≥1:40 if baseline is <1:10 or a ≥4-fold rise in  postvaccination  
HAI Ab titer if baseline is ≥1:10 . 
Overall Design  Synopsis : 
This is a Phase 3, randomized, observer -blind study to evaluate the safety, tolerability, and 
immunogenicity o f mRN A-1345, an mRNA vaccine targeting RSV, when given sequentially 
CCI
CCI
ModernaTX, Inc.  
mRNA -1345 -P304  Protocol  mRNA -1345  
Confidential  Page 13 (3 weeks apart)  or coad ministered with a HD quadrivalent seasonal influenza vaccine (Fluzone 
HD) in adults ≥65 years of age.  
All participants will participate in a Screening period (up to 28 days before Day 1), Intervention  
period (vaccine[s] and/or placebo administration on Day 1 and Day 22), and a Follow -up period 
(up to 7  month s). 
The study will enroll approximately 1900 medically stable adults ≥65 years of age. On Day 1, 
each participan t will receive 2 injections, one in each arm. On Day 22, each participant will 
receive 1 injection. All injections will be administered IM, in the deltoid muscle. Participants 
will be randomized to study arms as shown in the schema ( Section  1.2) to receive either 
1) Fluzone HD +mRN A-1345  μg on Day 1 followed by [CONTACT_14296] (0.9 % sodium chloride) on 
Day 22; or 2) Fluzone HD +placebo (0.9 % sodium chloride) on Day 1 followed by [CONTACT_14297] A-1345 
 μg on Day 22. 
Randomization will be stratified by [CONTACT_654] (65 to <75 years and ≥75 years  [approximately 10% ]). 
Brief Summary : 
The study aims to evaluate the safety and reactogenicity of mRN A-1345 RSV vaccine when 
coadministered with a HD quadrivalent seasonal influenza vaccine (Fluzone HD) in adults 
≥[ADDRESS_13582] 4 vaccine -matched influenza A and B strains.  
Study details include:  
• There will be 4in-person visits and 4 safety calls  (see the SoA [ Table  1]). 
• All participants will be asked to complete an eDiary for solicited local and systemic 
ARs for 7  days (ie, the day of study intervention dosing and 6 subsequent days) after 
dosing on Day  1 and Day  22. 
• Detection of unsolicited AEs will be through 21  days after each study intervention 
dosing (ie, the day of study intervention dosing and 20 subsequent days). Detection of 
MAAEs, AESI, SAEs, and AEs leading to discontinuation from study participation 
will continue through Month  [ADDRESS_13583] study injection  (EoS) or withdrawal  from 
the study . 
Number of Participants:  
Approximately 1900 participants will be randomized in a 1:1 ratio to the assigned study 
interventions.  
Study Arms and Duration : 
• The study will be composed of  2 study arms.  
• The total duration of the study participation is up to approximately 8 months  from the 
Screening Visit . 
CCI
CCI
ModernaTX, Inc.  
mRNA -1345 -P304  Protocol  mRNA -1345  
Confidential  Page 14 1.2. Schema   
Figure  1: Study Schema   
 
Abbreviations: EoS  = end of study; HD  = high dose; N  = number of participants.  
Note : A blood sample will be drawn at each in -person visit.  
       
            
             
      
           
                
                 
                           
              
                             
                          
               
              
                           
        
            
                                          
                   
                                      
                           
                  
ModernaTX, Inc.  
mRNA -1345 -P304  Protocol  mRNA -1345  
Confidential  Page 15 1.3. Schedule of Activities   
Table  1: Schedule of Activities  
Study Period  Screening  Intervention Period  Follow -up 
Visit Number  Screening  1 2 3 4 5 6 7 
Visit Month*  -1 1 1 1 1 2 3 6 
Visit Day  Screeninga D1a D8 D22 D29 D43b D91 D202/  
EoS 
Window Allowance (Days)  -28 N/A +3 +7 +3 -2 to +7 ±5 ±14 
Type of Visit  V V SC V SC V SC SC 
Informed consent, demographics, concomitant medications  
and vaccinations , and medical history  X – – – – – – – 
Inclusion/exclusion criteria  X X – – – – – – 
Physical examinationc X X – X – – – – 
Vital sign measurementsd X X – X – – – – 
Randomization  – X – – – – – – 
Blood  sample collection for humoral immunogenicitye – X – X – X – – 
Study vaccination (including a 30 -minute postdose 
observation period)d,f – X – X – – – – 
eDiary activation for recording solicited ARs (7  days)g – X – X – – – – 
eDiary  reviewg  X X X X    
Follow -up safety telephone callh – – X – X – X X 
Recording of unsolicited AEs  – X X X X X – – 
Concomitant medicationsi – X X X X X – – 
Recording of SAEs , AESIs,  MAAEs, AEs leading to 
discontinuation, and concomitant medications relevant to or 
for their treatmenth – X X X X X X X 
ModernaTX, Inc.  
mRNA -1345 -P304  Protocol  mRNA -1345  
Confidential  Page 16 Study Period  Screening  Intervention Period  Follow -up 
Visit Number  Screening  1 2 3 4 5 6 7 
Visit Month*  -1 1 1 1 1 2 3 6 
Visit Day  Screeninga D1a D8 D22 D29 D43b D91 D202/  
EoS 
Window Allowance (Days)  -28 N/A +3 +7 +3 -2 to +7 ±5 ±14 
Type of Visit  V V SC V SC V SC SC 
Recording of nonstudy vaccinationsh,i – X X X X X X X 
Study completion  – – – – – – – X 
Abbreviations: AE  = adverse event; AESI  = adverse event of special interest; AR  = adverse reaction; D  = Day; eDiary  = electronic diary; EoS  = end of study; 
IM = intramuscular; M = month; MAAE  = medically attended adverse event; N/A  = not applicable; RSV  =  respi[INVESTIGATOR_4345] ; SAE  = seriou s adverse 
event; SC  = safety telephone call; ; V = in-person visit ; – = indicated activity not performed on that day . 
*A month is defined as 30 days.  
Arm 1: Fluzone HD +mRN A-1345  μg on Day  1 followed by [CONTACT_14296] (0.9 % sodium chloride) on Day 22; 
Arm 2: Fluzone HD +placebo (0.9 % sodium chloride) on Day 1 followed by [CONTACT_14297] A-1345  μg on Day 22. 
a. The Screening Visit and Day 1 Visit may be performed on the same day or on different days  (see Section  5.3 for additional details) . 
b. If a participant cannot attend a scheduled in -person visit (with the exception of the Screening Visit, Day 1, and Day 22), a home visit is acceptable if 
performed by [CONTACT_14298].  
c. A complete  physical examination, including height and weight, will be performed at the Screening Visit.  Symptom -directed physical examinations will be 
performed at other study visits, if clinically indicated  (see Section  8.3.1  for additional details).  
d. Vital sign measurements include assessment of systolic and diastolic blood pressure, pulse rate, respi[INVESTIGATOR_697], and body temperature (preferred route i s 
oral)  (see Section  8.3.2  for additional details) . 
e. Blood samples for humoral immunogenicity  must be collected prior to administration of the study intervention on Day 1 and Day  22. 
f. All participants will be randomized to receive 2 IM injections, one in each arm, in the deltoid muscle  (Day  1) and 1 IM injection in the deltoid muscle 
(Day  22). 
g. At Day [ADDRESS_13584].  
CCI
CCI
ModernaTX, Inc.  
mRNA -1345 -P304  Protocol  mRNA -1345  
Confidential  Page 17 i. All concomitant medications and procedures will be recorded for 21  days following each vaccination (Day  1 through Day 43); all nonstudy vaccinations and 
concomitant medications relevant to or for the treatment of an SAE, AESI, or MAAE wil l be recorded from Day [ADDRESS_13585] study 
injection /EoS.  
 
ModernaTX, Inc.  
mRNA -1345 -P304  Protocol  mRNA -1345  
Confidential  Page 18 2. INTRODUCTION   
RSV has been identified as one of the important etiologies of acute  respi[INVESTIGATOR_14257] a major cause of illness in adults with certain 
comorbidities (“high risk”), including those with chronic lung and heart disease ( Falsey et al 
2005 ; Shi et al 2020 ). While most adults have been previously infected with RSV and therefore 
demonstrate some level of RSV protective immunity, the immune requirements for protection in 
older adults are not well understood. The level of hum oral response is a strong correlate of 
immune protection, as decreased serum neutralizing activity and/or decreased nasal 
RSV-specific IgA are risk factors for RSV infection, including more severe disease ( Walsh et al 
2013 ). Waning  cellular immunity may also play a role in the susceptibility of the elderly to RSV 
infections, as healthy adults older than [ADDRESS_13586] increased numbers of regulatory 
(immunosuppressive) T cells and fewer RS V-specific CD8+ T cells ( Crank et al 201 9; Kurzweil 
et al 2013 ; Looney et al 2002 ). Therefore, RSV remains a significant unmet medical need.  
The fusion glycoprotein of the RSV envelope is a conserved target of prote ctive nAbs for both 
serotypes of RSV: RS V-A and RS V-B. ModernaTX, Inc. (the Sponsor) has developed a 
rapid -response, proprietary vaccine platform based on a mRNA delivery system. The platform is 
based on the principle and observations that cells in vivo ca n take up mRNA, translate it, and 
then express protein viral antigen(s) on the cell surface. The delivered mRNA does not enter the 
cellular nucleus or interact with the genome, is nonreplicating, and is expressed transiently. The 
mRN A-1345 vaccine encodes for the RSV fusion glycoprotein that is stabilized in the prefusion 
conformation.  
Seasonal influenza viruses are estimated by [CONTACT_14299] 3 million to 5 million cases of 
severe illness and up to 650,000 deaths each year resulting in a challenge to pub lic health 
(WHO  2023). Influenza epi[INVESTIGATOR_14258] a seasonal circulation pattern with 
increased cases during the winter months in both the NH and SH ( Riedel et al 2019 ). Since 
influenza viruses continuously change through a process termed antigenic drift, the circulating 
viruses are actively monitored by a worldwide monitoring network coordinated by [CONTACT_14300] 
(Monto 2018 ). Based on the observed ci rculation patterns and antigenic changes, an expert panel 
recommends influenza virus strains to be used for vaccine manufacturing twice per year (once 
for the NH and once for the SH). Influenza A and influenza B viruses are the most relevant 
influenza viru ses for human infection. Therefore, current vaccine recommendations include 
1 influenza A H1N1 strain, 1 influenza A H3N2 strain, and 2 influenza B strains (covering the 
B/Victoria and B/Yamagata lineages).  
It is well accepted that the risk of complication s due to influenza increases with age ( Bartoszko 
and Loeb , 2021 ). Lower respi[INVESTIGATOR_6014], in cluding pneumonia, represent a substantial 
burden of illness in older adults. It is estimate d that lower respi[INVESTIGATOR_14259] 1.27 million deaths (95 % CI: 1.15 to 1.34 million) in older adults across 
195 countries in 2015 ( GBD 2015 ). An analysis of the US FluSurv -NET showed that 
hospi[INVESTIGATOR_14260] 75 to 8 4 years and ≥85 years were 1.4 to 3.0 and 2.2 to 
6.4 times greater, respectively, than rates for adults aged 65 to 74 years. In -hospi[INVESTIGATOR_14261] 3.8% of patients aged 65 to 74 years, 5.3% of patients aged 75 to 
84 years, an d 8.7% of patients aged ≥85 years ( Czaja et al 2019 ). Similarly, data from 
[ADDRESS_13587] excess mortality rates were found among patients 
aged 75 years and older (17.9 to 223.5 per 100,000) ( Graham 201 9). 
ModernaTX, Inc.  
mRNA -1345 -P304  Protocol  mRNA -1345  
Confidential  Page 19 Because of increased morbidity and mortality associated with influenza infections in older 
adults, Fluzone HD Quadrivalent vaccine is one of 3 influenza vaccines (along with Flublok® 
Quadrivalent and Fluad® Quadrivalent) that i s preferentially recommended for people 65  years 
and older. This preferential recommendation is new for the 2022 -2023 season.  
2.1. Study Rationale   
The Sponsor’s position is that the coadministration of mRN A-1345 with a seasonal influenza 
vaccine will allow people to receive both vaccines at once to reduce the number of visits and add 
to the uptake/convenience in people at risk for both RSV and influenza diseases.  
2.2. Background   
The Sponsor is using its mRNA -based platform to develop a custom manufactured  
LNP -encapsulated, mRNA -based vaccine to prevent disease associated with RSV infection. The 
vaccines  included in this clinical study are described below.  
mRN A-[ADDRESS_13588] cell through a conformational 
change to the postfusion state. The prefusion conformation was selected because it displays all 
the epi[INVESTIGATOR_14262] n (Crank et al 2019 ; Graham 2019 ; McLellan et al 2013 ; Ngwuta et al 2015 ). 
The mRN A-1345 vaccine is currently being evaluated in older adults for safety, reactogenicity, 
immunogenicity, or efficacy in 2 Phas e 1 studies ( mRN A-1345-P101, [STUDY_ID_REMOVED]  and 
mRN A-1230-P101, [STUDY_ID_REMOVED] ), a Phas e 1b open -label study ( mRNA -CRID -001, 
[STUDY_ID_REMOVED] ), a Phase 2/3 study ( mRN A-1345-P301, [STUDY_ID_REMOVED] ), and a Phase  3 study 
(mRN A-1345-P302, [STUDY_ID_REMOVED] ). 
At the time of the 30  Nov 2022 data cutoff date for the Phase 2/3 study ( mRN A-1345-P301, 
[STUDY_ID_REMOVED] ), the mRN A-1345 vaccine adm inistered as a single  µg dose demonstrated an 
acceptable reactogenicity profile and no new safety concerns were identified in the study 
population of adults ≥[ADDRESS_13589] RS V-confirmed LRTD  was demon strated with 
83.7% (95.88 % CI, 66.0, 92.2; p<0.0001) protection against RS V-LRTD with ≥2 symptoms and 
82.4% (96.36 % CI, 34.8, 95.3; p=0.0078) against RS V-LRTD with ≥3 symptoms.  
Licensed HD Influenza Vaccine (Fluzone HD  Quadrivalent ) 
Fluzone HD Quadrivalent is a vaccine manufactured by [CONTACT_14301].  and is indicated for 
active immunization for the prevention of influenza disease caused by [CONTACT_14302] A subtype 
CCI
ModernaTX, Inc.  
mRNA -1345 -P304  Protocol  mRNA -1345  
Confidential  Page 20 viruses and type B viruses contained in the vaccine . Fluzone HD Quadriva lent is indicated for 
use in persons ≥65 years of age.  
Fluzone HD Quadrivalent is a 4 -component flu vaccine containing  µg of HAs, and is 
supplied in prefilled syringes,  mL. Additional details about the vaccine are available in the 
package insert ( Fluzone® HD Quadrivalent package insert , 2023 ). 
2.3. Benefit/Risk Assessment   
Summaries of the potential risks and benefits of mRN A-[ADDRESS_13590] recent 
versions of the IB . 
2.3.1.  Risk Assessment   
There are no important identified risks currently identified for mRN A-1345. 
IM vaccination commonly precipi[INVESTIGATOR_14263] a transient, dose-dependent,  and self -limiting local 
inflammatory reaction. Systemic ARs may also occur after vaccination.  
Immediate systemic allergic reactions (eg, anaphylaxis) can occur following any vaccination. 
These reactions are very rare and are estimated to oc cur once per 450,000 vaccinations for 
vaccines that do not contain allergens such as gelatin or egg protein ( Zent et al 2002 ). As a 
precaution, all participants will remain under observation at the study site for at least 30 minutes  
after study injection.  
Vasovagal syncope (fainting) can occur before or after any vaccination, is usually triggered by 
[CONTACT_14303]. Therefore, 
it is important that standard preca utions and procedures be followed to avoid injury from 
fainting.  
IM vaccination commonly precipi[INVESTIGATOR_14263] a transient and self -limiting local inflammatory reaction. 
This typi[INVESTIGATOR_14264], erythema (redness), or swelling (hardness) at the injection site,  
which are mostly mild -to-moderate in severity and usually occur within [ADDRESS_13591]. Investigators and participants should be alert to the signs and symptoms o f myocarditis and 
pericarditis ( Gargano et al 2021 ). 
2.3.2.  Benefit Assessment   
Participants who receive mRN A-1345 may or may not directly benefit from the vaccination . In a 
Phase 3 pi[INVESTIGATOR_14265]  (mRNA -1345 -P301 , [STUDY_ID_REMOVED] ), the primary efficacy endpoint  
demonstrating v accine efficacy of 83.7% (95.88 % CI: 66. 0, 92.2; p<0.0001) against RS V-LRTD  
as defined by 2 or more symptoms  was achieved  for mRN A-1345. 
CCI
CCI
ModernaTX, Inc.  
mRNA -1345 -P304  Protocol  mRNA -1345  
Confidential  Page 21 Participants will be contributing to the process of developi[INVESTIGATOR_007] a new potentially prophylactic 
measure in an area of unmet medical need.  
2.3.3.  Overall Benefit /Risk Conclusion   
Appropriate eligibility criteria, as well as specific criteria for delaying the vaccination, are 
included in this protocol. The risk to participants in this study may be minimized by [CONTACT_14304].  
All safety findings will be closely monitored and reviewed by [CONTACT_14305].  An independ ent CEAC will review all 
suspected cases of myocarditis, pericarditis, and myopericarditis  (see additional details  in 
Section  [IP_ADDRESS] ). 
Considering the safety and efficacy data for mRN A-1345 to date, the Sponsor considers the 
potential benefits of participation to exceed the risks . 
ModernaTX, Inc.  
mRNA -1345 -P304  Protocol  mRNA -1345  
Confidential  Page 22 3. OBJECTIVES AND ENDPOINTS   
Table  2: Objectives and Endpoints  
Objectives  Endpoints  
Primary   
• To evaluate the safety and 
reactogenicity of mRN A-1345 RSV 
vaccine coad ministered with a HD 
quadrivalent seasonal influenza vaccine 
(Fluzone HD) . • Solicited local and systemic ARs through 7 days 
after each injection . 
• Unsolicited AEs through 21 days after each study 
injecti on. 
• MAAEs from Day [ADDRESS_13592] study 
injection /EoS . 
• AESI from Day  [ADDRESS_13593] study 
injection /EoS . 
• SAEs from Day  [ADDRESS_13594] study 
injection /EoS . 
• AEs leading to discontinuation from Day  [ADDRESS_13595] study injection /EoS . 
• To evaluate the impact of 
coad ministered HD quadrivalent 
seasonal influenza vaccine on the 
immune response to mRN A-[ADDRESS_13596] RS V-A and RS V-B. • GMT of serum RSV-A and RS V-B nAbs at Day 22 
(Arm 1 a) or Day  43 (Arm 2 b). 
• To evaluate the impact of 
coad ministered mRN A-[ADDRESS_13597] 4  vaccine -matched influenza A 
and B strains . • GMT of serum  anti-HA Ab level as measured by 
[CONTACT_14293]  22. 
Secondary   
• To further evaluate the effect of 
mRN A-1345 RSV vaccine 
coad ministered with a HD quadrivalent 
seasonal influenza vaccine on the 
immune response to RS V-A and 
RSV-B. • SRR c in RS V-A and RSV-B nAbs at Day  22 
(Arm  1) or Day  43 (Arm 2). 
• GMFR of postinjection RS V-A and RS V-B nAbs 
(Day  22 for Arm 1 and Day  43 for Arm 2) 
compared to baseline  (Day  1 for Arm 1 and Day  22 
for Arm 2). 
• Proportion of participants with ≥2 -fold increase in 
RSV -A and RSV -B nAbs at Day  22 (Arm 1) or 
Day 43 (Arm 2).  
ModernaTX, Inc.  
mRNA -1345 -P304  Protocol  mRNA -1345  
Confidential  Page 23 Objectives  Endpoints  
• To further evaluate the effect of 
mRN A-[ADDRESS_13598] 4  vaccine -
matched influenza A and B strains . • SCR d at Day  22 as measured by [CONTACT_14294] . 
• GMFR comparing Day 1 (baseline ) and Day  22 
measured by [CONTACT_14295] . 
Exploratory (may be performed)   
• To further evaluate the immune 
response across study vaccines . • GMC and GMFR of postinjection/ baseline titers of 
RSV bAbs. 
• Proportion of participants with ≥2 -fold and ≥4-fold 
increases in RS V bAb concentration  postinjection.  
• Frequency, specificities, or other endpoints to be 
determined, for the further characterization of 
immune responses . 
Abbreviations: Ab = antibody; AE = adverse event; AESI  = adverse event of special interest; AR  = adverse reaction; 
EoS = end of study; GMC  = geometric mean concentration; GMFR  = geometric mean fold rise; GMT  = geometric 
mean titer; HAI  = hemagglutination inhibition; HD = high dose; LLOQ  =  lower limit of quantification; 
nAb = neutralizing antibody; RSV  = respi[INVESTIGATOR_4345]; SAE  = serious adverse event ; 
SCR  = seroconversion rate; SRR  = seroresponse rate . 
a. Arm 1: Fluzone HD +mRN A-1345  μg on Day 1 followed by [CONTACT_14296] (0.9 % sodium chloride) on Day 22. 
b. Arm 2: Fluzone HD +placebo (0.9 % sodium chloride) on Day 1 followed by [CONTACT_14297] A-1345  μg on Day 22. 
c. SRR  is defined as postvaccination titers ≥4× LLOQ if baseline is <LLOQ or a ≥4-fold increase from baseline if 
baseline is ≥LLOQ.  
d. SCR is defined as postvaccination titer ≥1:40 if baseline is <1:10 or a ≥4-fold rise in  postvaccination HAI Ab 
titer if baseline is ≥1:10.  
 
CCI
CCI
ModernaTX, Inc.  
mRNA -1345 -P304  Protocol  mRNA -1345  
Confidential  Page 24 4. STUDY DESIGN   
4.1. Overall  Design   
This is a Phase  3, randomized, observer -blind study to evaluate the safety, tolerability, and  
immunogenicity of mRN A-1345, an mRNA vaccine targeting RSV, when given sequentially 
(3 weeks apart)  or coad ministered with a HD quadrivalent seasonal influenza vaccine (Fluzone 
HD) in adults ≥65 years of age.  
All participants will participate in a Screening period (up to 28  days before Day 1), Intervention  
period (vaccine[s] and/or placebo administration on Day  1 and Day  22), and a Follow -up period 
(up to 7  month s). 
The study will enroll approximately 1900 medically stable adults ≥65 years of age. On Day  1, 
each participant will receive 2 injections, one in each arm. On Day  22, each participant will 
receive 1 injection. All injections will be administered IM, in the deltoid muscle. Participants 
will be randomized to study arms as shown in Table  4 to receive either 1) Fluzone 
HD+mRN A-1345  μg on Day 1 followed by [CONTACT_14296] (0.9 % sodium chloride) on Day  22 
(Arm  1); or 2) Fluzone HD +placebo (0.9 % sodium chloride) on Day  1 followed by [CONTACT_14297] A-1345 
 μg on Day  22 (Arm  2). 
4.2. Scientific Rationale for Study Design   
The mRN A-1345-P304 study will  evaluate the safety and immunogenicity of mRN A-1345  μg 
when coadministered with a commercial influenza vaccine (Fluzon e HD) and compare it with 
administration of Fluzone HD followed by [CONTACT_14297] A-1345 21  days later in medically stable older 
adults ≥65 years of age.  This is a randomized, observer -blinded study . 
In this study, only p articipants ≥65 years of age  were considered due to the preferentially 
recommended  influenza Fluzone HD Quadrivalent vaccine  and the Sponsor’s position that the 
coadministration of mRN A-1345 with a seasonal influenza vaccine will allow people to receive 
both vaccines at once to reduc e the number of visits and add to the uptake/convenience in people 
at risk for both RSV and influenza diseases , further  described in Section  2. Justification for Do se  
Participants will receive 1 dose of mRN A-1345  μg administered on either Day  1 or Day  22 
(refer to Table  3). The  μg dose was chosen  based on the observed reactogenicity and 
immunogenicity profiles in clinical Phas e 1, 2, and 3 studies conducted with mRN A-1345. 
Selected dose level for the Phase 2/3 study in adults >60 years:  Based on the Study 
mRN A-1345-P101 Phas e 1 data in adults aged 65 to 79 years, a single  µg injection was 
selected to be evaluated in the mRN A-1345-P301 Phase 2/3 pi[INVESTIGATOR_14266], 
based on an optimal combination of an acceptable safety profile and boosting and persistence of 
RSV nAb titers. At the  µg dose level, the reported rate of any local or systemic solicited AR 
was 72.3%, with injection site pain the most commonly reported (65.9%). Most of the  
participants reporting any solicited AR at this dose level experienced mild, Grad e 1 severity 
(59.6%), with lower rates of moderate, Grade 2 severity (6.4%) observed. In comparison, the 
reported rate of any local or systemic solicited AR in the placebo gr oup was 45.5%.  
CCI
CCI
CCI
CCI
CCI
CCI
CCI
ModernaTX, Inc.  
mRNA -1345 -P304  Protocol  mRNA -1345  
Confidential  Page 25 Results from a prespecified interim analysis of the ongoing pi[INVESTIGATOR_14267] >60 years  of age , mRN A-1345-P301 ( Section  2.2), demonstrate that the primary efficacy 
objectives were met, including:  
• Vaccine efficacy of 83.7% (95.88 % CI: 66.0, 92.2) against RS V-LRTD, defined by 
≥2 symptoms and 82.4% (96.36 % CI: 34.8, 95.3), defined by ≥3symptoms.  
• mRN A-[ADDRESS_13599] scheduled 
procedure as shown in the SoA ( Table  1) for the last participant in the study.  
A participant is considered to have completed the study if he or she ha s completed all periods of 
the study, including the last visit or scheduled procedure as shown in the SoA ( Table  1). 
ModernaTX, Inc.  
mRNA -1345 -P304  Protocol  mRNA -1345  
Confidential  Page 26 5. STUDY POPULATION   
5.1. Inclusion Criteria   
Participants are eligible to be included in the study only if all of the following criteria apply:  
Age 
1. Adults ≥65 years of age, at the time of signing informed consent (Screening  Visit or 
the day of the Randomization Visit).  
Type of Participant and Disease Characteristics  
2. Participants may have one or more chronic medical diagnoses, but should be 
medically stable as assessed by:  
• Absence of changes in medical therapy within 60  days of Day 1 due to treatment 
failure or toxicity,  
• Absence of serious or significant medical events within 30 days of Day 1, and  
• Absence of known, current, and life -limiting diagnoses which, in the opi[INVESTIGATOR_684] , would make completion of the protocol unlikely.  
Sex and Contraceptive/Barrier Requirements  
3. A participant assigned female at birth is eligible to participate if they are 
postmenopausal or not a person of childbearing potential.  
Informed Consent  
4. Capable of giving signed informed consent which includes compliance with the 
requirements and restrictions listed in the ICF and in the protocol  (see 
Section  10.1.3 ). 
Other Inclusion Criteria  
5. Investigator assessment that participant understands and is willing to comply with 
protocol -mandated follow -up, including all procedures and eDiary completion.  
6. Acce ss to inbound and outbound telephone communication with caregivers and study 
staff.  
5.2. Exclusion Criteria   
Participants are excluded from the study if any of the following criteria a pply:  
Medical Conditions  
1. Acutely ill or febrile (temperature ≥38.0℃ [100.4°F]) within [ADDRESS_13600] with someone with laboratory -confirmed influenza and/or RSV  
infection or with someone who has been treated with antiviral the rapi[INVESTIGATOR_14268] 
(eg, Tamiflu®) within the past [ADDRESS_13601] participant safety, assessment of safety endpoints, 
assessment of immune response, or adherence to study procedures. Clinically 
unstable is defined as a diagnosis or condition requiring significant changes in 
management or medication within 60  days prior to Day 1 and includes ongoing 
workup of an undiagnosed illness that could lead to a new diagnosis or condition.  
• Asymptomatic conditions and c onditions with no clinically significant end organ 
involvement (eg, mild hypertension, dyslipi[INVESTIGATOR_035]) are not exclusionary, if they are 
being appropriately managed and are clinically stable (ie, unlikely to result in 
symptomatic illness within the time cour se of this study). Illnesses or conditions may 
be exclusionary, even if otherwise stable, due to therapi[INVESTIGATOR_14269] (eg, 
immune modifying treatments), at the discretion of the Investigator . 
• Participants who have undergone surgical procedures with in 7 days prior to each 
study intervention  or are scheduled to undergo a surgical procedure within 21 days 
after each study intervention dosing are also excluded. However, minor surgical 
procedures under local anesthesia (eg, excision of skin lesion) or di agnostic 
procedures (eg, colonoscopy) are allowed.  
4. Reported history of congenital or acquired immunodeficiency, immunosuppressive 
condition or immune -mediated disease, asplenia, or recurrent severe infections. The 
following conditions are permitted at the discretion of the Investigator : 
• Participants who are HIV positive and on antiviral therapy with CD4  count 
≥350 cells/mm3 and HIV RNA ≤500  copi[INVESTIGATOR_014]/mL within the past 12  months.  
• Participants with immune -mediated diseases which are stable (eg, Hashimoto’s 
thyroiditis and typ e 1 diabetes) or conditions such as asthma, psoriasis, vitiligo, gout, 
alopecia areata, or auto immune  ovarian failure, which do not require systemic 
immunosuppressants per Exclusion Criterion # 14. 
5. Dermatologic conditions that could affect lo cal solicited AR assessments (eg, tattoos; 
psoriasis patches affecting skin over the deltoid areas).  
6. Participant has tested positive for influenza or RSV by [CONTACT_14306] -
approved testing methods  ≤[ADDRESS_13602] not returned to baseline  after their convalescent period 
will also be excluded.  
8. Reported history of anaphylaxis or severe hypersensitivity reaction after receipt of the 
mRN A-1345 vaccine or commercially available  influenza vaccines and any 
components of the mRN A-1345 vaccine or commercially available  influenza 
vaccines.  
9. History of Guillain -Barré syndrome.  
10. Reported history of bleeding disorder that is considered a contrain dication to IM 
injection or phlebotomy.  
ModernaTX, Inc.  
mRNA -1345 -P304  Protocol  mRNA -1345  
Confidential  Page 28 11. History of malignancy within previous 5 years (excluding nonmelanoma skin cancer).  
12. Any medical, psychiatric, or occupational condition, including reported history of 
drug or alcohol abuse, that, in the opi[INVESTIGATOR_14270], might pose additional 
risk due to participation in the study or could interfere with the interpretation of study 
results.  
13. Any history of dementia or any medical condition that moderately or severely impairs 
cognition. (Note: if deemed necess ary for clinical evaluation, the Investigator  can use 
tools such as the Mini -Mental State Examination, Mini -Cog, or Montreal Cognitive 
Assessment to determine cognition levels of the participant).  
Prior/Concomitant Therapy  
14. Received systemic immunosuppressa nts for >14 days in total within 6 months  prior to 
Day 1 (for corticosteroids, ≥10 mg/day of prednisone or equivalent) or is anticipating 
the need for systemic immunosuppressive treatment at any time during participation 
in the study. Inhaled, nasal , ophthalmic , and topi[INVESTIGATOR_14271]. Intra -
articular and epi[INVESTIGATOR_14272] 28  days before and/or 
after study intervention dosing.  
15. Participant has received systemic Igs or blood products within [ADDRESS_13603] immune 
responses (eg, infliximab) within 90  days prior to Day 1, or plan to receive them, are 
also excluded.  
16. Participant has received or plans to receive any vaccine authorized or approved by a 
local health agency ≤28  days prior to study injections (Day  1 and Day  22) or plans to 
receive a vaccine authorized or approved by a local health agency within  28 days 
after study injections . 
17. Participant has received a seasonal influenza vaccine or any other investigational 
influenza vaccine ≤ 6 months  prior to Day 1. 
18. Participant has received any RSV vaccine (authorized/approved by [CONTACT_14307]) prior to Day 1. 
19. Participant is not aware whether they have received an influenza vaccine in the most 
recent influenza season (in the prior 12  month s). 
20. Participant has been treated with antiviral therapi[INVESTIGATOR_14268] (eg, Tamiflu) within 
6 month s prior to Day  1. 
Prior/Concurrent Clinical Study Experience  
21. Participated in an interventional clinical study within 28  days prior to the Day 1 Visit 
based on the medical history interview or plans to do so while participating in this 
study. Participants m ay continue in prior interventional study follow -up activities, as 
long as it does not involve further investigational treatment other than the study 
intervention described in this protocol (Note: interventions such as counseling, 
biofeedback , and cognitiv e therapy are not exclusionary).  
ModernaTX, Inc.  
mRNA -1345 -P304  Protocol  mRNA -1345  
Confidential  Page 29 Other Exclusion Criteria  
22. Participant has donated ≥450  mL of blood products within 28  days prior to the 
Screening Visit or plans to donate blood products during the study.  
23. Participant is working or has worked as study personnel or is an immediate family 
member or household member of study personnel, study clinic staff , or Sponsor 
personnel.  
5.3. Screen Failures   
A screen failure occurs when a participant who has consented to participate in the clinical study 
is not subsequently assigned to study intervention. A minimal set of screen failure information is 
required to ensure transparent reporting of screen  failure participants to meet the Consolidated 
Standards of Reporting Trials publishing requirements and to respond to queries from regulatory 
authorities. Minimal information includes demography, screen failure details, eligibility criteria, 
and any SAE.  
Individuals who do not meet the criteria for participation in this study (screen failure) may be 
rescreened one time within the 28 -day screening window if they will be eligible upon 
rescreening . 
5.4. Criteria for Temporarily Delaying the Administration of Study  
Intervention   
Body temperature ( oral preferred) must be measured on the study intervention  visit before 
dosing . The following events constitute criteria for delay of study  interv ention dosing, and if any 
of these events occur at the time scheduled for dosing, the participant may receive the study  
intervention dosing at a later date within the time window specified in the SoA ( Table  1), or the 
participant may be discontinued from dosing at the discretion of the Investigator  (Section  7): 
• Acute moderate or severe infection with or without fever at the time of study 
intervention dosing.  
• Fever, defined as body temperature ≥38.0°C/≥100.4°F at the time of study 
intervention dosi ng. 
Participants  may be contact[CONTACT_14308]-evaluated for eligibility. If the Investigator  determines that the participant’s health on the day 
of dosing temporarily precludes study intervention , the visit sh ould be rescheduled within the 
allowed interval for that visit.
ModernaTX, Inc.  
mRNA -1345 -P304  Protocol  mRNA -1345  
Confidential  Page 30 6. STUDY INTERVENTIONS AND CONCOMITANT THERAPY   
Study interventions are all prespecified, investigational and noninvestigational medicinal 
products, medical devices,  and other interventions (eg, surgical and behavioral) intended to be  
administered to the study participants during the study conduct.  
6.1. Study Interventions Administered   
Fluzone HD and mRNA -1345 (Study Arm  1) or Fluzone HD and placebo (Study Arm  2) will be 
administered as IM injection s, one in each  deltoid muscle on Day  1, according to the procedures 
specified in the Pharmacy Manual. On Day  22, placebo (Study Arm  1) or mRNA -1345 (Study 
Arm 2) will be administered as an IM injection into the deltoid muscle,  as specified in the 
Pharmacy Manual . The arm (left and/or r ight) will not be documented in a way that identifies in 
which arm that the vaccine or placebo has been administered. It will be recorded by [CONTACT_14309]/blinded personnel be fore unblinding is authorized . 
Participants will be monitored for a minimum of 30 minutes after administration of the study  
intervention. Assessments will include vital sign measurements and monitoring for solicited ARs 
as shown in the SoA ( Table  1). 
Further instructions for the preparation and administration of mRN A-1345 are described in the 
Pharmacy Manual.  
The study interventions administered are lis ted in Table  3. 
Table  3: Study Interventions Administered   
Intervention Name  [CONTACT_14297] A-1345 Fluzone HD Placebo  
Concentration   µg/vial   mL/syringe  0.9% sodium chloride 
(normal saline)  
Formulation  Suspension  for 
Injection  Suspension for 
Injection  Sterile liquid  for 
Injection  
Route of 
Administration  IM IM IM 
Abbreviations: HD = high dose; IM = intramuscular.  
Study Intervention Packaging and Labeling  
The study intervention used in this study will be prepared, packaged, and labeled in accordance 
with the standard operating procedures of ModernaTX, Inc. or those of its  designee, CFR Title 
21, Good Manufacturing Practice guidelines, ICH Guidance for Industry, GCP guidelines, 
guidelines for Quality System Regulations, and applicable regulations.  The mRNA -1345  will be 
provided in vials , Fluzone HD  in syr inges . Each will be labeled as required per country 
requirement . 
CCI
CCI
ModernaTX, Inc.  
mRNA -1345 -P304  Protocol  mRNA -1345  
Confidential  Page 31 Study Arms and Dosing Regimens  
The study arms and dosing regimens are listed in  Table  4. 
Table  4: Study Arms and Dosing Regimens   
Arm Title  Arm 1 Arm 2 
Arm Description  Day 1: Fluzone HD +mRN A-1345  µg 
followed by  
[CONTACT_2006] 22: Placebo  Day 1: Fluzone HD +Placebo  
followed by  
[CONTACT_2006] 22: mRN A-1345  µg 
Abbreviation: HD  = high dose.  
6.2.  Preparation, Handling, Storage,  and Accountability   
1. The Investigator or designee must confirm appropriate conditions (eg, temperature) have 
been maintained during transit for all study intervention received, an d any discrepancies 
are reported and resolved before use of the study intervention.  
2. Only participants enrolled in the study may receive study intervention, and only 
authorized site staff may supply, prepare, or administer study intervention.  
3. All study intervention must be stored in a secure, environmentally controlled, and 
monitored (manual or automated) area in accordance with the labeled storage conditions 
with access limited to the Investigator and authorized site staff.  
4. The Investigator  or authorized site staff  are responsible for study intervention 
accountability, reconciliation, and record maintenance (ie, receipt, reconciliation, and 
final disposition records).  
5. Further guidance and information for the final disposition of unused study in terventions 
are provided in the Pharmacy Manual . 
6.3. Assignment to Study Intervention   
All participants will be centrally assigned to randomized study intervention using an 
IVRS/IWRS.  Before the study is initiated, the telephone number and call -in directions for the 
IVRS and/or the log -in information and directions for the IWRS will be provided to each site.  
Randomization will be stratified by [CONTACT_654] (65 to <75 years and ≥75 years [approx imately 10%]).  
Study intervention will be dispensed at the study visits as summarized in the SoA ( Table  1). 
Returned study intervention should not be r edispensed to the participants.  
6.4. Blinding   
Refer to Section  9.1 for additional details on blinding.  
As this is an observer -blind study, the Investigator , study clinic staff , study participants, site 
monitors, and Sponsor personnel (or its designees) will be blinded to the study intervention 
administered until the study database is locked and unblinded (with the following exceptions) : 
CCI
CCI
ModernaTX, Inc.  
mRNA -1345 -P304  Protocol  mRNA -1345  
Confidential  Page 32 • Unblinded personnel (of limited number) will be assigned to vaccine accountability 
procedures and will prepare the study int ervention for all participants. These 
personnel will have no study functions other than study intervention management, 
documentation, accountability, preparation, and administration. They will not be 
involved in participant evaluations and will not reveal the identity of the study 
intervention to either the participant or the blinded clinic personnel involved in the 
conduct of the study unless this information is necessary in the case of an emergency.  
• Unblinded study clinic staff  will administer the study i ntervention. They will not be 
involved in assessments of any study endpoints.  
• Unblinded site monitors, not involved in other aspects of monitoring, will be assigned 
as the study intervention accountability monitors. They will have responsibilities to 
ensur e that sites are following all proper study intervention accountability, 
preparation, and administration procedures.  
6.4.1.  Unblinding   
Investigators  may unblind the intervention assignment for any participant with an SAE. If the 
SAE requires that an expedited regulatory report be sent to one or more regulatory agencies, a 
copy of the report, identifying the participant’s intervention assignment, may b e sent to 
Investigators in accordance with local regulations and/or Sponsor policy . 
The IVRS/IWRS will be programmed with blind -breaking instructions. In case of an emergency, 
the Investigator has the sole responsibility for determining if unblinding of a participants’ 
intervention assignment is warranted. Participant safety must always be the first consideration in 
making such a determination. If the Investigator decides that unblinding is warranted, the 
Investigator may contact [CONTACT_14310] a participant’s 
intervention assignment unless this could delay emergency treatment for the participant. If a 
participant’s intervention assignment is unblinded, the Sponsor must be notified within [ADDRESS_13604] observation of  
medically qualified study staff, and study intervention administration will be appropriately 
recorded (date and time) in the eCRF. Qualified staff will confirm that the participant has 
received the entire dose of the study intervention. If a participant d oes not receive the study 
intervention, the reason for the missed dose will be recorded. Data will be reconciled with site 
accountability records to assess compliance.  
The study clinic staff  are responsible for ensuring that participants comply with the al lowed 
study visit windows. If a participant misses a visit, every effort should be made to contact [CONTACT_14311] a visit within the defined visit window specified in the SoA ( Table  1). 
If a participant does not complete a visit within the time window, that visit will be classified as a 
missed visit and the participant will continue with subsequent scheduled study visits. All safety 
requirements of the missed visit will be captured and included in the subsequent visit.  
ModernaTX, Inc.  
mRNA -[ADDRESS_13605] be performed . 
6.9. Prior and Concomitant Therapy   
Any medication or vaccine (including OTC  or prescription medicines, recreational drugs, 
vitamins, and/or herbal supplements) or other specific categories of interest  (see below)  that the 
participant is receiving at the time of enrollment or receives during the study must be recorded 
along with:  
• Reason for use.  
• Dates of administration including start and end dates.  
• Dosage information including dose and frequency.  
Specific categories of interest:  
• All prior medications (including any prescription or OTC  medications, vaccines, or 
blood products) take n by [CONTACT_14312] 28  days before providing informed 
consent.  
• Any licensed seasonal influenza vaccine administered in the prior 12  months.  
• Any licensed/authorized or investigational COVID -19 vaccine administered at any 
time before study interv ention administration.  
• Any vaccine (authorized or investigational) administered in the prior [ADDRESS_13606] the following information in 
the eCRF:  
• All nonstudy vaccinations administered within the period starting 28  days before the 
study injection and through EoS.  
• All concomitant medications taken for 21 days following each vaccination (Day  1 
through Day  43). Antipyretics and analgesics taken prophylactically (ie, taken in the 
absence of any symptoms in anticipation of an injection reaction) will be recorded as 
such.  
• Any concomitant medications used to  prevent or treat COVID -19, RSV disease, or 
any other infectious disease symptoms.  
• Any concomitant medications relevant to or for the treatment of an SAE, AESI, or an 
MAAE from Day [ADDRESS_13607] study injection /EoS.  
• The participant will be asked in the eDiary if they have taken any antipyretic or 
analgesic to treat or prevent fever or pain within 7  days after each vaccination, 
including the day of injection. Reported antipyretic or analgesic medications should 
be recorded in the source do cument by [CONTACT_14313] (eg, SCs). 
• All concomitant procedures/surgeries at any time during the study period after study 
intervention dosing.  
Concomitant medications ( including vaccinations) will be coded using the WHO Drug Global 
dictionary.  
If a participant takes a prohibited drug therapy, the Investigator  and the medical monitor will 
make a joint decision about continuing or withholding further assessment of the participant based 
on the time the medication was administered, and the drug’s pharmacology and 
pharmacokinetics . The Sponsor will decide  whether t he use of the medication will compromise 
the participant’s safety or interpretation of the study data. It is the Investigator ’s responsibility to 
ensure that details regarding the concomitant medications are adequately recorded in the eCRF.  
6.9.3.  Concomitant Med ications and Vaccines That May Lead to the Elimination of a 
Participant from the Per Protocol Analyses   
The use of the following concomitant medications and/or vaccines may not re quire withdrawal 
of the participant from the study but may determine a participant’s evaluability in the PP analysis 
(analysis sets are described in Section  9.4): 
• Any investigational or nonregistered product (drug or vaccine) other than the study 
interventions used during the study period.  
• A nonstudy vaccine (including authorized or approved vaccines for the prevention of 
COVID -19 regardless of the type of vaccine) a dministered during the period from 
28 days before through 21 days after each study injection  (until Day 43) . 
ModernaTX, Inc.  
mRNA -1345 -P304  Protocol  mRNA -1345  
Confidential  Page 35 • Nonstudy influenza or RSV vaccine at any time during the study.  
• Igs and/or any blood products administered during the study period.  
• Medications that suppress the immune system . 
ModernaTX, Inc.  
mRNA -1345 -P304  Protocol  mRNA -1345  
Confidential  Page 36 7. DISCONTINUATION OF STUDY INTERVENTION AND 
PARTICIPANT DISCONTINUATION/WITHDRAWAL   
Discontinuation of specific sites or of the study as a whole are  detailed in Section  10.1.10 . 
7.1. Discontinuation of Study Intervention   
In rare instances, it may be necessary for a participant to permanently discontinue study 
intervention. If study intervention is permanently discontinued, the participant should, if at all 
possible,  remain in the study for follow -up and for any further eva luations that need to be 
completed  (see the SoA [ Table  1]). 
7.2. Participant Discontinuation/ Withdrawal from the Study   
• A participant may withdraw from the study at any time at the participant’s own 
request for any reason (or without providing any reason).  
• A participant may be withdrawn at any time at the discretion of the Investiga tor for 
safety, behavioral, or compliance reasons.  
• At the time of discontinuing from the study, if possible, an end of study call should be 
conducted, as shown in the SoA  (Table  1). See the SoA for data to be collected at the 
time of study discontinuation and follow -up and for any further evaluations that need 
to be completed.  
• The participant will be permanently discon tinued from the study intervention and the 
study at that time.  
• A participant who withdraws from the study will not be replaced.  
• If the participant  withdraws consent  for disclos ure of future information, the Sponsor  
may retain and continue to use any data c ollected before such a withdrawal of 
consent . 
• If a participant  withdraws from the study, the participant  may request destruction of 
any samples taken and not tested , and the Investigator must document this in the site 
study records . 
• The Sponsor  will contin ue to retain and use all research results that have already been 
collected for the study evaluation. All biological samples that have already been 
collected may be retained and analyzed at a later date (or as permitted by [CONTACT_13125]) . 
From an analys is perspective, a “withdrawal” from the study refers to a situation wherein a 
participant does not return for the final visit foreseen in the protocol. All data collected until the 
date of withdrawal or last contact [CONTACT_14314]. A participant is 
considered a “withdrawal” from the study when no study procedure has occurred, no follow -up 
has been performed, and no further information has been collected for that participant from the 
date of withdrawal or last contact.  
Information relative to the withdrawal will be documented in EDC . The Investigator  will 
document whether the decision to withdraw a participant from the study was made by a 
ModernaTX, Inc.  
mRNA -1345 -P304  Protocol  mRNA -1345  
Confidential  Page 37 participant, or by [CONTACT_737] , as well as which of the following possible reasons was 
responsible for withdrawal:  
• AE 
• Death  
• Lack of efficacy  
• Lost to follow -up 
• Noncompliance with study intervention  
• Other  
• Physician decision  
• Protocol deviation  
• Screen failure  
• Study terminated by [CONTACT_2728]  
• Withdrawal by [CONTACT_3445]  
• Withdrawal due to solicited ARs /reactogenicity  
Participants who are withdrawn from the study because of SAEs/AEs must be clearly 
distinguished from participants who are withdrawn for other reasons. Investigators will follow -
up with participants who are withdrawn from the study  because of an SAE or AE until resolution 
of the event.  
7.3. Lost to Follow -up  
If a participant does not complete a visit within the time window specified in the SoA ( Table  1), 
every effort should still be made to complete the assessments for that visit (even though outside 
of the defined visit window); the participant will continue with subsequent scheduled study  visits 
per their original schedule (ie, relative to their Day  1 visit). If a participant still does not 
complete the visit after all these efforts, the visit will be classified as missed and all safety 
requirements of the missed visit will be captured and  included in the subsequent visit.  
A participant  will be considered lost to follow -up if the participant  repeatedly fails to return for 
scheduled visits and is unable to be contact[CONTACT_9298].  
The following actions must be taken if a participant  fails to return to the clinic for a required 
study visit:  
• The site must attempt to contact [CONTACT_14315], counsel the participant on the importance of maintaining the 
assigned visit schedule and ascertai n whether the participant wishes to and/or should 
continue in the study.  
• Before a participant is deemed lost to follow -up, the Investigator  or designee must 
make every effort to regain contact [CONTACT_6635] (where possible, 3 telephone 
calls, and if  necessary, a certified letter to the participant’s last known mailing 
ModernaTX, Inc.  
mRNA -1345 -P304  Protocol  mRNA -1345  
Confidential  Page 38 address or local equivalent methods). These contact [CONTACT_14316]’s medical record.  
• Should the participant continue to be unreachable, the participant  will be considered 
to have withdrawn from the study.  
• A participant should not  be considered lost to follow -up until due diligence has been 
completed.  
7.4. Pause Rules   
Not applicable . 
ModernaTX, Inc.  
mRNA -1345 -P304  Protocol  mRNA -1345  
Confidential  Page 39 8. STUDY ASSESSMENTS AND PROCEDURES   
• Study procedures and their timing are summarized in the SoA  (Table  1). Protocol 
waiver s or exemptions are not allowed.  
• Adherence to the study design requirements, including those specified in the SoA  
(Table  1), is essential and required for study conduct.  
• All screening evaluations must be completed and reviewed to confirm that  potential 
participant s meet all eligibility criteria. The Investigator  will maintain a screening log 
to record details of all participant s screened and to confirm eligibility or record 
reasons for sc reening failure, as applicable.  
• Procedures conducted as part of the participant’s routine clinical management (eg, 
blood count) and obtained before signing of the ICF may be utilized for screening or 
baseline purposes provided the procedures met the protocol -specified criteria and 
were performed within the timeframe defined in the SoA  (Table  1). 
• In the event of a significant study -continuity issue (eg, caused by a pandemic), 
alternate strategies for participant visits, assessments, medication distribution , and  
monitoring may be i mplemented by [CONTACT_14317] , as per local 
health authority/ethics requirements.  
• Study results that could unblind the study will not be reported to investigative sites or 
other blinded personnel until the study has been unblinded.  
• If a visit cannot be scheduled within the indicated allowable window and/or the 
participant misses the visit, this is considered a protocol deviation. However, the visit 
should still be completed, if possible, to collect study data. Subsequent visits shoul d 
be scheduled at the originally planned number of days after Day 1 defined in the SoA 
(Table  1). 
The maximum amount of blood collected from each parti cipant over the duration of the study, 
including any extra assessments that may be required, will not exceed blood limits specified by 
[CONTACT_427]. Sample collection on Day 1 and Day  22 (ie, blood) must be performed prior to 
study intervention dosing . 
Repeat or unscheduled samples may be taken for safety reasons or for technical issues with the 
samples. Further details are provided in both the ICF and Laboratory Reference Manual.  
8.1. Demography   
Demographic information relating to the participant’s sex, age, and race will be recorded at 
Screening  in EDC . 
The m edical history of each participant will be collected and recorded  in EDC . Significant 
findings that were present prior to the signature [CONTACT_14361] . 
ModernaTX, Inc.  
mRNA -1345 -P304  Protocol  mRNA -1345  
Confidential  Page 40 8.2. Immunogenicity Assessments   
Blood samples for immunogenicity assessments will be collected at the time points i ndicated in 
the SoA ( Table  1). Immunogenicity assessments will be performed for all participants. The 
following analytes may be measured:  
• RSV serum Abs, including nAbs  and bAbs . 
• Influenza virus serum Abs, measured by [CONTACT_14294].  
Sample aliquots will be designed to ensure that backup samples are available and vial volumes 
are likely to be adequate for future testing needs. The actual date and time of ea ch sample will be 
noted. Unique sample identification will be utilized to maintain the blind at the laboratory at all 
times and allow for automated sample tracking and housing. Handling and preparation of the 
samples for analysis, as well as shippi[INVESTIGATOR_6926] s torage requirements, will be provided in a separate 
study manual.  
Measurement of Ab levels will be performed in a laboratory designated by [CONTACT_1034].  
According to the IC F (Section  10.1.3 ), excess serum from the blood samples collected for 
immunogenicity testing may be used for future research, which may be performed at the 
discretion of the Sponsor to further characterize the immune response to RSV and influenza vi rus 
and for additional assay development.  
8.3. Safety Assessments   
Safety assessments will include monitoring and recording of the following for each participant 
according to the SoA ( Table  1): 
• Solicited local and systemic ARs that occur during the 7  days following each vaccine 
administration (ie, the day of study intervention dosing and 6 subsequent days 
[Days  1-7 and Days  22-28]). Solicited ARs will be recorded daily using eDiaries. 
Local solicited ARs will be recorded separately for each injection site . eDiary review 
by [CONTACT_14318] 1 -Day 7 and Day 22 -28. Additional review of 
the eDiary will occur at Day 8 and Day 29 between the site and the participant during 
the safety telephone call s. 
• Unsolicited AEs observed or reported from the day of each injection and 
20 subsequent days.  Unsolicited AEs are AEs that are not included in the protocol -
defined solicited A Rs. 
• SAEs  from the time of signing ICF through Month 6 (EoS) after the last study 
intervention dosing . 
• AESIs, MAAEs, and AEs leading to discontinuation from study participation from 
vaccination on Day [ADDRESS_13608] study intervention dosing  (EoS) 
or withdrawal  from the study.  
• Vital sign measurements  
• Physical examination findings  
• Concomitant medications and non study  vaccinations  
ModernaTX, Inc.  
mRNA -1345 -P304  Protocol  mRNA -1345  
Confidential  Page 41 • Concomitant procedures  
8.3.1.  Physical Examinations   
A complete  physical examination , including height and weight, will be performed at the 
Screening Visit. A complete  physical examination is not needed on Day  1 if Screening occurs 
within 7  days of Day  1.  
• A complete physical examination will include, at a minimum, assessments of the 
cardiovascular, respi[INVESTIGATOR_696], gastrointestinal, and neurological systems. Height and 
weig ht will also be measured and recorded.  
• Investigators should pay special attention to clinical signs related to previous serious 
illnesses.  
• On the day of study intervention administration, before administration, the arms 
receiving the injection(s) should be  examined and the associated lymph nodes should 
be evaluated . 
Any clinically significant finding identified during the Screening Visit should be reported as 
medical history, and during study visits should be reported as a MAAE . 
Symptom -directed physical ex aminations will be performed at other in -person visits, if clinically 
indicated  (Table  1). Any clinically significant finding identified during a symp tom-directed 
physical examination should be reported as an AE.  
Investigators should pay special attention to clinical signs related to previous serious illnesses.  
8.3.2.  Vital Signs   
Vital signs including systolic and diastolic blood pressures, pulse rate, respi[INVESTIGATOR_697], and body 
temperature will be measured at the time points indicated in the SoA ( Table  1). The preferred 
route of temperature assessment is oral.  
The participant will be seated for at least [ADDRESS_13609] 30 minutes after study intervention dosing (before participants are discharged from the 
study site). If vital signs are clinically concerning, participant should not be dosed. When 
applica ble, vital sign measurements should be performed before blood collection.  Vital signs will 
be collected at other clinical visits only in conjunction with a symptom -directed physical 
examination.  
Febrile participants on the study intervention dosing day (fe ver is defined as a body temperature 
≥38.0°C/100.4°F) may be rescheduled within the relevant window periods.  Criteria for delay of 
study intervention dosing are provided in Section  5.4. 
An abnormal vital sign measurement should be assessed to determine if it meets AE reporting 
criteria per protocol and reported as an AE in the EDC, if appropriate. The Investigator  will 
continue to monitor the participant with additional assessments until the vital sign value has 
reached the reference range, returns to the vital sign value at baseline , is considered stable, or 
until the Investigator  determines that follow -up is no l onger medically necessary.  
ModernaTX, Inc.  
mRNA -[ADDRESS_13610] confirm they are willing to complete an eDiary for 
7-day reactogenicity after e ach vaccination. The local and systemic ARs that will be solicited by 
[CONTACT_14319]  7. 
Solicited local and systemic reactogenicity ARs will be collected on the 7  days following each 
vaccine administration (ie, the day of study intervention dosing and 6 subsequent days [Days  1-7 
and Days  22-28]). Details on the recording of solicited local and systemic ARs are included in 
Section  10.2. 
At the dosing visit, participants will record data into the eDiary starting approximately 
30 minutes after study intervention dosing under supervision of the clinic staff to ensure 
successful entry of assessments. The 30 -minute observation period is an opportunity for clinic 
staff to train the participant on eDiary completion requirements. The clinic staff will perform any 
retraining as necessary.  
At each dosin g visit, participants will be instructed or reminded on thermometer usage to 
measure body temperature, ruler usage to measure injection site erythema (redness) and 
swelling/induration (hardness), and self -assessment for localized axillary (underarm) swelli ng or 
tenderness ipsilateral (on the same) side as the injection arm(s) during the 7 days after study 
injection(s). Daily oral temperature measurement should be performed at approximately the same 
time each day using the thermometer provided by [CONTACT_14320]. 
The participant will be trained on how to complete the eDiary questions according to the SoA 
(Table  1). If eDiary questions result in identificat ion of relevant safety events according to the 
study period or symptoms, a follow -up safety call will be triggered  (see Section  8.3.4 ). The 
information obtained du ring the safety call should be recorded in the appropriate source 
documentation.  
If a participant does not respond to the eDiary questions according to the SoA, clinic staff will 
follow -up with the participant.  
8.3.4.  Safety Phone Call s  
A safety phone call is a telephone call made to the participant by [CONTACT_14321]. This call 
will follow a script, which will facilitate the collection of relevant safety information. Safety 
phone calls will follow a schedule for each participant, as shown in the SoA ( Table  1). The 
participant will be interviewed accordi ng to the script about occurrence of unsolicited AEs, 
MAAEs, SAEs, AESIs, AEs leading to discontinuation from study participation, concomitant 
medications associated with those events, and any non study  vaccinations. All safety information 
collected from th e phone call must be documented in the source documents as described by [CONTACT_14322]. An unscheduled follow -up 
safety call may be triggered if an eDiary record results in identification of a relev ant safety event. 
A safety phone call may trigger an USV . 
8.4. Adverse Events , Serious Adverse Events, and Other Safety 
Reporting   
The definitions of AEs, SAEs, solicited ARs, and unsolicited AEs can be found in Section  10.2. 
ModernaTX, Inc.  
mRNA -1345 -P304  Protocol  mRNA -1345  
Confidential  Page 43 The Investigator  and any qualified designees are res ponsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible for following 
up all AEs. This includes events reported by [CONTACT_2299] (or, when appropriate, by a 
caregiver, surrogate, or the pa rticipant’s legally authorized representative).  
The method of recording, evaluating, and assessing causality of AEs and SAEs and the 
procedures for completing and transmitting SAE reports are  provided in  Section  10.2. 
8.4.1.  Time Period and Frequency for Collecting AE and SAE Information   
All SAEs  will be collecte d from the time  of signing ICF through Month  [ADDRESS_13611] study 
injection/ EoS. AESI, MAAE s, and AEs leading to discontinuation from study participation will 
be collected from the start of study intervention dosing until Month  6 after each study injection  
(EoS) or withdra wal from the study , at the timepoints specified in the SoA ( Table  1). 
All solicited local and systemic ARs will be collected 7 days  after study intervention dosing  on 
Day 1 and Day 22 (ie, the day of study intervention dosing and 6  subsequent days).  
All unsol icited AEs will be collected through  the 2 1 days following each study  intervention 
dosing (ie, the day of study  intervention dosing and 20 subsequent days).  
Medical occurrences that begin before the start of study  intervention but after obtaining informed 
consent (and that are not SAEs) will be recorded as medical history/current medical conditions, 
not as AEs ; however, if the condition worsens at any time after study intervention  administration, 
it will be recorde d and reported as an AE.  
All SAEs will be recorded and reported to the Sponsor  or designee immediately and under no 
circumstance should this exceed [ADDRESS_13612] promptly notify the Sponsor . 
8.4.2.  Method of Detecting AEs and SAEs   
An eDiary  has specifically been designed for this study by [CONTACT_14323] (see Section  8.3.3 ). At the time of consent, the participants must confirm they will be 
willing to complete the eDiary to record solicited ARs that occur during the 7  days following 
each vaccine administration (ie, the day of study intervention dosing  and 6 subsequent days 
[Days  1-7 and Days  22-28]). The diary will include prelisted ARs (solicited ARs) and intensity 
scales.  
At every in -person visit or telephone contact, participants will be asked a standard ques tion to 
elicit any medically related changes in their well -being (including surveillance for respi[INVESTIGATOR_14273]) for detection of unsolicited AEs, according to the scripts provided. 
Participants will also be asked if they have been hospit alized, had any accidents, used any new 
medications, changed concomitant medication regimens (both prescription and OTC  
medications), or had any non study  vaccinations.  
ModernaTX, Inc.  
mRNA -[ADDRESS_13613] pursue 
and obtain information adequate to determine the outcome of the AE and to assess whether the 
AE meets the criteria for classification as an SAE or AESI requiring immediate notification to 
the Sponsor or its designated representative.  
Care will  be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended and 
nonleading verbal questioning of the participant is the preferred method to inquire about AE 
occurrences.  
8.4.3.  Follow -up of AEs and SAEs   
After the initial AE/SAE report, the Investigator  is required to proactively follow each 
participant at subsequent visits/contacts.  All SAEs and AESIs  (as defined in Section  10.2.4 ) will 
be followed until resolution, stabilization, the event is otherwise explained, or the participant is 
lost to follow -up (as defined in Section  7.3). Further information on follow -up procedures is 
provided in  Section  10.2. 
8.4.4.  Regulatory Reporting Requirements for SAEs   
Prompt notification by [CONTACT_14324] a study 
intervention under clinical investigation are met.  
The Sponsor has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a study inte rvention under clinical investigation. The 
Sponsor will comply with country -specific regulatory requirements relating to safety reporting to 
the regulatory authority, IRBs, and Investigator s. For example, for reports that are required to be 
submitted to th e European Union, individual case safety report s, will be submitted via the 
EudraVigilance Clinical Trial Module  Gateway.  
An Investigator  who receives an Investigator  safety report describing an SAE or other specific 
safety information (eg, summary or list ing of SAEs) from the Sponsor will review and then file it 
along with the IB/package insert and will notify the IRB, if appropriate according to local 
requirements.  
For expedited reporting purposes, the expectedness of SAEs will be assessed against the 
investigational treatment regimen the participant is receiving at the time of the event. AE terms 
not listed as expected events in the IB/package insert for investigational product(s) and 
comparator(s) will be considered unexpected.  
Investigator safety reports must be prepared for suspected unexpected serious ARs according to 
local regulatory requirements and Sponsor policy and forwarded to Investigator s as necessary.  
8.4.5.  Solicited Adverse Reactions   
Solicited ARs are a subset of AEs consisting of selected signs and symptoms that participants are 
asked to record/report. In this study, the solicited ARs are reactogenicity events. The term 
“reactogenicity” refers to  the occurrence of transient adverse effects associated with study 
intervention dosing. The eDiary will solicit daily participant reporting of ARs using a structured 
ModernaTX, Inc.  
mRNA -[ADDRESS_13614] such occurrences in the eDiary on the day of each study 
intervention dosing and 6 subsequent days.  
Severity grading of reactogenicity will occur automatically based on participant entry into the 
eDiary according to the grading scales presented Section  10.2, which are modified from the 
Toxicity Grading Scales for Healthy Adult and Adolescent Volunteers Enrolled in Preventive 
Vaccine Clinical Trials ( DHHS  2007 ). All s olicited ARs (local and systemic) will be considered 
causally related to dosing.  
If a participant reports a solicited AR with onset during the solicited period, but they did not 
record the event in the eDiary, then the event should be recorded by [CONTACT_14325].  
If the event starts during the solicited period, but continues beyond 7  days after dosing, the 
participants should notify the site to provide an end date and close out the event in EDC, where 
reactogenicity is collected.  
If the participant repor ted an event that started after the solicited period (ie, beyond 7  days after 
dosing), it should be recorded as an AE in EDC. Causality for these events will be determined 
per assessment by [CONTACT_737].  
Any solicited AR that meets any of the following  criteria must be entered into the participant’s 
source document and must also be recorded by [CONTACT_14326], where reactogenicity is 
collected : 
• Solicited local or systemic AR that results in a visit to a healthcare practitioner 
(MAAE ). 
• Solicited local or systemic AR lasting beyond [ADDRESS_13615] study  intervention dosing.  
• Solicited local or systemic AR that leads to participant discontinuation from study 
participation.  
• Solicited local or systemic AR that otherwise meets the definition of an SAE.  
8.4.6.  Medic ally Attended Adverse Events   
A MAAE is an AE that leads to an unscheduled visit to a healthcare practitioner. This would 
include visits to a study site for unscheduled assessment s (eg, rash assessment, abnormal 
laboratory follow -up) and visits to healthcare practitioners external to the study site (eg, 
emergency room, urgent care, primary care physician). Investigators will review unsolicited AEs 
for the occurrence of any MAAEs. Unsolicited AEs will be captured in EDC . 
8.4.7.  Adverse Events of Special Interest   
The definition of AESI is provided in Section  10.2.4 . 
AESI for this protocol are listed in Section  10.3. 
Investigators should report all events which fall into the categories as an AESI per the reporting 
processes specified in Section  10.2.6 . 
ModernaTX, Inc.  
mRNA -1345 -P304  Protocol  mRNA -1345  
Confidential  Page 46 [IP_ADDRESS].  Anaphylaxis   
All suspected cases of anaphylaxis associated with study intervention dosing should be recorded 
as AESIs and reported as an S AE (Section  10.2.6 ), based on criteria for a medically important 
event, unless the event meets other serious criteria. For reporting purposes, a par ticipant who 
displays signs/symptoms consistent with anaphylaxis as shown below should be reported as a 
potential case of anaphylaxis. This is provided as general guidance for Investigator s and is based 
on the Brighton Collaboration case definiti on (Rüggeberg et al 2007 ). 
Anaphylaxis is an acute hypersensitive reaction with multi organ  system involvement that can 
present as, or rapi[INVESTIGATOR_14274], a severe life -threatening reaction. It may occur following 
exposure to allerge ns from a variety of sources. Anaphylaxis is a clinical syndrome characterized 
by [CONTACT_716]:  
• Sudden onset AND  
• Rapid progression of signs and symptoms AND  
• Involving 2 or more organ systems, as follows:  
− Skin/mucosal: urticaria (hives), generalized erythema, angioedema, generalized 
pruritus with skin rash, generalized prickle sensation, red and itchy eyes.  
− Cardiovascular: measured hypotension, clinical diagnosis of uncompensated 
shock, loss of consciousness or decreased level of consciousness, eviden ce of 
reduced peripheral circulation.  
− Respi[INVESTIGATOR_696]: bilateral wheeze (bronchospasm), difficulty breathing, stridor, upper 
airway swelling (lip, tongue, throat, uvula, or larynx), respi[INVESTIGATOR_1506], 
persistent dry cough, hoarse voice, sensation of throat closure, sneezing, 
rhinorrhea.  
− Gastrointestinal: diarrhea, abdominal pain, nausea, vomiting.  
[IP_ADDRESS].  Myocarditis and/or Pericarditis   
A case of suspected, probable, or confirmed myocarditis, pericarditis, or myopericarditis should  
be reported as an AESI, even if it does not meet criteria per the CDC case definition. The event 
should also be reported as an SAE if it meets ser iousn ess criteria ( see Section  10.2.2 ). 
An independent CEAC will review all suspected cases of myocarditis, pericarditis, and 
myopericarditis, which are reported in ongoing interventional clinical trials p er the CEAC 
charter, to determine if they meet CDC criteria for “probable” or “confirmed” events 
(Section  [IP_ADDRESS] ). 
The CDC Working Case Definitions are provide d in Section  10.4 as guidance . 
8.5. Pharmacokinetics   
Pharmacokinetic  parameters are not evaluated in this study . 
8.6. Pharmacodynamics   
Pharmacodynamic parameters are not evaluated in this study.  
ModernaTX, Inc.  
mRNA -1345 -P304  Protocol  mRNA -1345  
Confidential  Page 47 8.7. Biomarkers   
Biomarkers are not evaluated in thi s study.  
ModernaTX, Inc.  
mRNA -1345 -P304  Protocol  mRNA -1345  
Confidential  Page 48 9. STATISTICAL CONSIDERATIONS   
This section summarizes the planned statistical analysis strategy and procedures for the study. 
The details of the statistical analys es will be provided in the SAP, which will be finalized before 
the clinical database lock for the study and treatment unblinding. If, after the study has begun, 
but prior to any unblinding, changes are made to primary and/or secondary 
objectives/hypotheses, or the  statistical methods related to those hypotheses, then the protocol 
will be amended (consistent with ICH Guideline E9). Changes to exploratory analyses made 
after the protocol has been finalized, along with an explanation as to when and why they 
occurred, will be listed in the SAP or CSR for the study. Ad hoc exploratory analyses, if any, 
will be clearly identified in the CSR.  
9.1. Blinding and Responsibility for Analyses   
An independen t unblinded statistical and programming team s will perform the preplanned 
primary analysis (Section  9.6.1 ) and a final analysis . Prespecified Sponsor team members will be 
unblinded for these analyses  and will not communicate the results to the blinded Investigator s, 
study clinic staff , clinical monitors, or participants.  
The dosing assignment will be concealed by [CONTACT_14327] a secure location that is not accessible or visible to other study clinic 
staff. An opaque sleeve/blinding label over the syringe used for injection will maintain the blind 
at the time of injection, as the doses co ntaining mRN A-1345, placebo , and Fluzone HD have a 
different appearance . Only delegated unblinded study clinic staff  will conduct the injection 
procedure. Once the injection s are completed, only the blinded study clinic staff  will perform 
further assessments and interact with the participants. Access to the randomization code will be 
strictly controlled at the pharmacy.  
Procedures for breaking the blind in the case of a medical emergency are provided in  Section  6.4. 
9.2. Statistical Hypothesis   
The immunogenicity primary objectives are to evaluate the effect of coad ministered influenza 
vaccine with mRN A-[ADDRESS_13616] on the Immune Response to RS V-A: 
Coprimary endpoints based on RS V-A GMT 21  days after mRN A-1345 administration:  
The null hypothesis H10: immunogenicity response to mRN A-1345 in partic ipants who received 
mRN A-1345 co administered  with Fluzone HD, as measured by [CONTACT_14328] 22 (Arm 1) using 
RSV-A nAb assay, is inferior compared with that in participants who received mRN A-1345 
sequentially with Fluzone HD, as measured by [CONTACT_14328] 43 (Arm 2) using RS V-A nAb 
assay. The noninferiority in the GMT in participants who received mRN A-1345 co administered  
with Fluzone HD compared with that of participants who received mRN A-1345 sequentially 
with Fluzone HD will be demonstrated by [CONTACT_14329] 95 % CI of the GMR of ruling out 0.667 
(ie, LB >0.667) using a noninferiority margin of 1.5. The GMR is the ratio of the GMT of 
RSV-A nAbs in participants  who received mRN A-[ADDRESS_13617] on the Immune Response to RS V-B: 
Coprimary endpoints based on RS V-B GMT 21  days after mRN A-1345 administration:  
The null hypothesis H20: immunogenicity response t o mRN A-1345 in participants who received 
mRN A-1345 coad ministered with Fluzone HD ( Arm 1), as measured by [CONTACT_14328] 22 
(Arm 1) using RS V-B nAb assay, is inferior compared with that in participants who received 
mRN A-1345 sequentially with Fluzone HD, as me asured by [CONTACT_14328] 43 (Arm 2) using 
RSV-B nAb assay. The noninferiority in the GMT in participants who received mRN A-1345 
coad ministered with Fluzone HD compared with that of participants who received mRN A-1345 
sequentially with Fluzone HD will be demonstrated by [CONTACT_14329] 95 % CI of the GMR of 
ruling out 0.667 (ie, LB >0.667) using a noninferiority margin of 1.5. The GMR is the ratio of 
the GMT of RS V-B nAbs in participants who received mRN A-[ADDRESS_13618] on the Immune Response to Influenza:  
Coprimary endpoints based on GMT 21  days after Fluzone HD administration:  
The null hypothes es H30 to H60: immunogenicity response to Fluzone HD in participants who 
received mRN A-1345 coad ministered with Fluzone HD, as measured by [CONTACT_14330] -
HA Abs for each of the 4 influenza strains at Day 22 (both Arm 1 and Arm 2) using HAI assay, 
is inferior compared with that in participants who received mRN A-1345 sequentially with 
Fluzone HD. For each of the 4 influenza strains, the noninferiority in the GMT in participants 
who received mRN A-1345 coad ministered with Fluzone HD compared with that of  participants 
who received mRN A-1345 sequentially with Fluzone HD will be demonstrated by [CONTACT_14329] 
95% CI of the GMR of ruling out 0.667 (ie, LB >0.667) using a noninferiority margin of 1.5. 
The GMR is the ratio of the GMT of anti -HA Abs in participants who received mRN A-[ADDRESS_13619] on the Immune Response to RS V-A: 
Seconda ry endpoints based on SRR 21  days after mRN A-1345 administration:  
The null hypothesis H70: immunogenicity response to mRN A-1345 in participants who received 
mRN A-1345 coad ministered with Fluzone HD, as measured by [CONTACT_14331] V-A nAbs at Day 22 
(Arm 1), is in ferior compared with that in participants who received mRN A-1345 sequentially 
with Fluzone HD, as measured by [CONTACT_14331] V-A nAbs at Day 43 (Arm 2). The noninferiority in 
the SRR in participants who received mRN A-1345 coad ministered with Fluzone HD compared 
with that of participants who received mRN A-1345 sequentially with Fluzone HD will be 
demonstrated by [CONTACT_14329] 95 % CI of the SRR difference of ruling out -10% (ie, LB > -10%) 
using a noninferiority margin of 10%. The SRR difference is the SRR of RS V-A nAb in 
participants who received mRN A-[ADDRESS_13620] on the Immune Response to RS V-B: 
Secondary  endpoints based on SRR 21  days after mRN A-1345 administration:  
The null hypothesis H80: immunogenicity response to mRN A-1345 in participants who received 
mRN A-1345 coad ministered with Fluzone HD, as measured by [CONTACT_14331] V-B nAbs at Day 22 
(Arm 1), is infe rior compared with that in participants who received mRN A-1345 sequentially 
with Fluzone HD, as measured by [CONTACT_14331] V-B nAbs at Day 43(Arm 2). The noninferiority in 
the SRR in participants who received mRN A-1345 coad ministered with Fluzone HD compared 
with that of participants who received mRN A-1345 sequentially with Fluzone HD will be 
demonstrated by [CONTACT_14329] 95 % CI of the SRR difference of ruling out -10% (ie, LB >-10%) 
using a noninferiority margin of 10%. The SRR difference is the SRR of RS V-B nAb in 
participants who received mRN A-[ADDRESS_13621] on the Immune Response to Influenza Based 
on Seroconversion From Baseline:  
Secondary endpoint based on SCR 21  days after Fluzone HD administration:  
The null hypotheses H90 to H120: immunogenicity response to Fluzone HD  in participants who 
received mRN A-1345 coad ministered with Fluzone HD , as measured by [CONTACT_14332]-HA Abs for each influenza strain at Day 22 (for both Arm 1 and Arm 2) using HAI assay, is 
inferior compared with that in participants who received mRN A-1345 sequentially with Fluzone 
HD. The noninferiority in SCR in partic ipants who received mRN A-1345 coad ministered with 
Fluzone HD  compared with that of participants who received mRN A-1345 sequentially with 
Fluzone HD  will be demonstrated by [CONTACT_14329] 95 % CI of the SCR difference of ruling 
out -10% (ie, LB >-10%) using a  noninferiority margin of 10%. The SCR difference is the SCR 
of anti -HA Abs in participants who received mRN A-1345 coad ministered with Fluzone HD  
minus the SCR of anti -HA Abs in participants who received mRN A-1345 sequentially with 
Fluzone HD . 
9.3. Sample Size Determination   
The study will plan to randomize approximately 1900 participants in a 1:1 ratio, with 
approximately 950  participants receiving Fluzone HD + mRN A-1345 followed by [CONTACT_14296] 
(Arm 1) and 950  participants receiving Fluzone HD + placebo followed by [CONTACT_14297] A-1345 
(Arm  2). 
With approximately 950  participants in each group, the study has approximately 95% probability 
to observe at least 1 participant with an AE a t a true 0.3 % AE rate in that group.  
Assuming approximately 10% of participants are ineligible to be included in the PP Set , 
[ADDRESS_13622] 98.5% power to demonstrate the 
noninferiority of the immune resp onse to RS V-A and RS V-B, as measured by [CONTACT_14333] V-A 
and RS V-B nAb at Day 22 (Arm 1) or Day 43 (Arm 2) in participants receiving mRN A-[ADDRESS_13623] 91.3%. Sample size justification for the 
coprimary endpoints is shown in Table  5. 
Table  5: Sample Size Justification  
Coprimary 
Endpoints  Number of Evaluable 
Participants (with 10% 
Ineligible for the PP 
Set) α Standard 
Deviation  GMR 
Assumption  NI 
Margin  Power  
mRN A-1345 noninferiority ( 2-sided test)  
RSV-A GMT  
Day 22 (Arm 1) 
versus  
Day 43 (Arm 2) 855 0.05 1.5 GMR=0.9  1.5 98.5%  
RSV-B GMT  
Day 22 (Arm 1) 
versus  
Day 43 (Arm 2) 855 0.05 1.5 GMR=0.9  1.5 98.5%  
Fluzone HD noninferiority ( 2-sided test)  
GMT  
Day 22 (Arm 1) 
versus  
Day 22 (Arm 2) 855 0.05 1.5 GMR=0.9  1.5 98.5%  
Overall power to show noninferiority on both mRN A-1345 and Fluzone HD  91.3%  
Abbreviations: GMR  = geometric mean titer ratio; GMT  = geometric mean titer; HD = high dose; 
NI = noninferiority; PP = per protocol . 
9.4. Analysis Sets   
The a nalysis sets are described in  Table  6: 
Table  6: Analysis Set s  
Set Description  
Randomized Set  Includes all participants who are randomized in the study, regardless 
of the participant’s treatment status in the study. Participants will be 
included in the treatment  group to which they are randomized.  
Full Analysis Set ( FAS) All randomized participants who received any study intervention . 
Participants will be included in the treatment  group to which they are 
randomly assigned.  
Per Protocol ( PP) Set Includes all participants in the FAS that received the assigned study 
interven tion dose according to protocol, complied with 
immunogenicity blood sampling to have a baseline  and at least [ADDRESS_13624] the immune response. The PP Set will be the 
ModernaTX, Inc.  
mRNA -1345 -P304  Protocol  mRNA -1345  
Confidential  Page 52 Set Description  
primary pop ulation used for the analysis of immunogenicity data. 
Participants will be included in the treatment  group to which they are 
randomly assigned.  
Solicited Safety Set  Includes all randomized participants who received any study 
intervention  and contributed any solicited AR data. The Solicited 
Safety Set will be used for the analyses of solicited ARs and 
participants will be included in the treatment  group corresponding to 
the study intervention  they actually received.  
Safety Set  Includes all  randomized participants who receive any study 
intervention . Participants will be included in the treatment  group 
corresponding to the study intervention  they actually received for the 
analysis of safety data using the Safety Set.  
Abbreviations: AR  = adverse reaction; FAS  = full analysis set; I MP = investigational medicine product; PP  = per 
protocol.  
9.5. Statistical Analyses   
The SAP will be developed and finalized before database  lock and will describe the preplanned 
statistical analysis details/data derivations, the participant populations to be included in the 
analyses, and procedures for accounting for missing and/or unused data.  
This section is a summary of the planned statist ical analyses of the primary and secondary 
endpoints.  
9.5.1.  Immunogenicity Analyses   
The primary analysis population for immunogenicity will be the PP Set, unless otherwise 
specified.  If the number of participants in the FAS and PP Set differs (defined as the difference 
divided by [CONTACT_14334]) by [CONTACT_726] 10%, supportive analyses 
of immunogenicity may be conducted using the FAS.  
The coprimary endpoin ts include the GMT of RS V-A/RS V-B nAb titers at Day 22 (Arm  1) and 
Day 43 (Arm  2) and GMT of anti -HA Ab titers  at Day 22 for each influenza strain. For each 
coprimary endpoint regarding GMT, the GMR will be estimated using an analysis of covariance 
model o n the log -transformed titers, with the treatment  group and log-transformed baseline titers 
as a fixed covariate , adjusted for stratified age group used for randomization . The GLSM and its 
corresponding 95 % CI in a log -transformed scale estimated from the m odel will be 
back -transformed to obtain these estimates in the original scale as an estimate of the GMT and its 
95% CI. The GMR, estimated by [CONTACT_14335] 2-sided 95 % CI, 
will be provided to assess the treatment difference. The corresponding 2-sided 95 % CI of the 
GMR will be provided to assess the difference in the immune response between the 2 treatment  
groups. For each coprimary endpoint regarding GMT, the noninferior ity of the GMT will be 
demonstrated if the LB of the 95 % CI of the GMR is >0.667.  
The SRR of RS V-A/RS V-B nAbs is defined as proportion of participants with post vaccination  
titers ≥4×LLOQ if baseline is <LLOQ or a ≥4-fold increase from baseline if baseline is ≥LLOQ . 
The SCR of an influenza strain is defined as proportion of participants with a post vaccination  
ModernaTX, Inc.  
mRNA -1345 -P304  Protocol  mRNA -1345  
Confidential  Page 53 titer ≥1:40 if baseline is <1:10 or a ≥4-fold rise in post vaccination  HAI Ab titer if baseline is 
≥1:10. 
The number and percentage of participants with  SRR  at Day 22 (Arm 1) and Day 43 (Arm 2) or 
SCR  at Day 22 will be provided with 2-sided 95 % CI using the Clopper -Pearson method. For 
secondary endpoints regarding SRR and SCR, the Miettinen -Nurminen’s method will be used to 
calculate the 95 % CI for the difference in the SRR or SCR at corresponding timepoint  between 
the treatment  groups. For each strain, the noninferiority of SRR  or SCR  will be considered 
demonstrated if the LB of the 95 % CI of the SRR  or SCR  difference is > -10% based on a 
noninferiority margin of 10%.  
For the immunogenicity endpoints, the GM T/GMC  ratio of specific Abs, with the corresponding 
95% CI at each time point , and geometric mean fold rise ( GMFR ) of specific Ab titers, with the 
corresponding 95 % CI at each postbaseline timepoint  over preinjection baseline, will be 
provided by [CONTACT_1570]. The 95 % CIs will be calculated based on the t -distribution of the 
log-transformed values then back -transformed  to the original scale . Descriptive summary 
statistics, including the m edian, minimum, and maximum values, will also be provided.  
For summarizations of the GMT/GMC ratios, Ab titers reported as below the LLOQ will be 
replaced by 0.5×LLOQ. Values that are greater than the ULOQ will be converted to the ULOQ if 
actual values are  not available.  
The proportion of participants with at least 2 -fold and SRR  titers/concentration (relative to 
baseline) will be provided by [CONTACT_14336] 2-sided 95 % CI using the Clopper -Pearson 
method  as well.  
Descriptive statistics (including 95% CI s) of the immunogenicity endpoints will also be provided 
by [CONTACT_14337] (65 to 74 years, and ≥75 years).  
9.5.2.  Safety Analyses   
All safety analyses will be based on the Safety Set, except summaries of solicited ARs, which 
will be based on the Solicited Safety Set. All safety analyses will be provided by [CONTACT_6490], and by [CONTACT_14338], as applicable, unless otherwise speci fied. 
Safety and reactogenicity will be assessed by [CONTACT_14339], including 
solicited ARs (local and systemic ARs), unsolicited AEs, treatment -related AEs, severe AEs, 
SAEs, MAAEs, AEs leading to discontinuation from study par ticipation, AESIs, vital sign 
measurements, and physical examination findings.  
The number and percentage of participants with any solicited local AR or solicited systemic AR 
during the 7 -day follow -up period after each study intervention will be summarized . A 2-sided 
95% CI using the Clopper -Pearson method will also be provided for the percentage of 
participants with any solicited AR.  
The number and percentage of participants with unsolicited AEs, treatment -related AEs, severe 
AEs, SAEs, AESIs, MAAEs, and A Es leading to discontinuation from study participation will be 
summarized. Unsolicited AEs will be coded according to the MedDRA for AR terminology and 
presented by [CONTACT_14340].  
Solicited ARs will be coded according to the MedDRA for AR terminology. The toxicity grading 
scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials . 
ModernaTX, Inc.  
mRNA -1345 -P304  Protocol  mRNA -1345  
Confidential  Page 54 Unsolicited AEs will be presented by [CONTACT_14340].  The 
number and percentage o f participants with unsolicited AEs, SAEs, AESIs, MAAEs, severe AEs, 
and AEs leading to discontinuation from study participation in the study will be summarized.  
The number of events of unsolicited AEs, SAEs, AESIs, MAAEs, and AEs leading to 
discontinuatio n will be reported in summary tables accordingly. For all other safety parameters, 
descriptive summary statistics will be provided. Further details will be described in the SAP . 
9.5.3.  Exploratory Analy ses (May Be Performed)   
The GMC and GMFR of post injection /baseline  titers to RS V bAbs, the proportion of participants 
with ≥2 -fold and 4-fold ( SRR ) increases in RS V bAb concentration will be summarized.  
The frequency, specificities, or other endpoints to be determined for the further characterization 
of immune responses may also be explored. Exploratory analyses not addressed in this section 
will be described in the SAP before database lock.  
9.6. Planned Analyses   
9.6.1.  Primary  Analysis   
The primary analysis of safety and immunogenicity will be performed after all participants have 
completed the Da y 43 Visit. All data relevant to the primary study analysis through the Day  43 
Visit will be cleaned and locked for the primary analysis (ie, data that are as clean as possible) 
and a report may be generated. The primary analysis will be performed by a sep arate team of 
unblinded programmers and statisticians.  The SAP will describe the planned primary  analyses in 
greater detail s. 
9.6.2.  Final Analysis   
The final analysis of all endpoints will be performed after all participants have completed 
Day 202/EoS.  Results of the analysis will be presented in a final CSR . 
9.6.3.  Multiplicity   
A sequential/hierarchical testing procedure will be used to control the overall Typ e 1 error rate at 
0.05 (2 -sided) over the primary endpoints and secondary endpoints.  
The coprimary endpoints will be tested at the planned primary analysis at a [ADDRESS_13625] achieved statistical significance.  
ModernaTX, Inc.  
mRNA -1345 -P304  Protocol  mRNA -1345  
Confidential  Page 55 10. SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS   
10.1. Appendix  1: Regulatory, Ethical, and Study Oversight 
Considerations   
10.1.1.  Regulatory and Ethical Considerations   
• This s tudy will be conducted in accordance with the protocol and with the following:  
− Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizations of Medical 
Sciences international ethical guidelines . 
− Applicable ICH GCP guidelines . 
− Applicable laws and regulations . 
• The protocol, protocol amendments, ICF, IB, and other relevant documents (eg, 
advertisements) must be submitted to an IRB/IEC by [CONTACT_14341]/IEC before the study is initiated.  
• Any amendments to the protocol will require IRB/IEC approval before 
implementation of changes made to the study design, except for changes necessary to 
eliminate an immediate hazard to study parti cipants.  
• Protocols and any substantial amendments to the protocol will require health 
authority approval prior to initiation except for changes necessary to eliminate an 
immediate hazard to study participants.  
• The Investigator  will be responsible for the f ollowing , as applicable : 
− Providing written summaries of the status of the study to the IRB/IEC annually or 
more frequently in accordance with the requirements, policies, and procedures 
established by [CONTACT_1201]/IEC . 
− Notifying the IRB/IEC of SAEs or other sign ificant safety findings as required by 
[CONTACT_1744]/IEC procedures . 
− Providing oversight of the conduct of the study at the site and adherence to 
requirements of 21 CFR, ICH guidelines, the IRB/IEC, European regulation 
536/2014 for clinical studies , and all other ap plicable local regulations . 
10.1.2.  Financial Disclosure   
Investigators and Subinvestigators will provide the Sponsor  with sufficient, accurate financial 
information as requested to allow the Sponsor  to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory authorities. Investigators are at 
minimum responsible for prov iding information on financial interests during the course of the 
study and for 1 year after completion of the study.  
ModernaTX, Inc.  
mRNA -1345 -P304  Protocol  mRNA -1345  
Confidential  Page 56 10.1.3.  Informed Consent Process   
• The Investigator  or the Investigato r’s representative will explain the nature of the 
study, including the risks and benefits, to the potential participant and answer all 
questions regarding the study.  
• Potential participants must be informed that their participation is voluntary. They will 
be required to sign a statement of informed consent that meets the requirements of 
21 CFR  50, local regulations, ICH guidelines, privacy and data protection 
requirements, where applicable, and the IRB/IEC or study center.  
• The medical record must include a s tatement that written informed consent was 
obtained before the participant was enrolled in the study and the date the written 
consent was obtained. The authorized person obtaining the informed consent must 
also sign the ICF.  
• Participants must be reconsente d to the most current version of the ICF(s) during their 
participation in the study.  
• A copy of the ICF(s) must be provided to the participant.  
A participant who is rescreened is not required to sign another ICF if the rescreening occurs 
within [ADDRESS_13626] be approved by [CONTACT_1201]/IEC. 
10.1.5.  Data Protection   
• Participants will be assigned a unique identifier by [CONTACT_1034] . Any participant 
records or datasets that are transferred to the Sponsor  will contain the identifier only; 
participant names or any information which would make the participant identi fiable 
will not be transferred.  
ModernaTX, Inc.  
mRNA -1345 -P304  Protocol  mRNA -1345  
Confidential  Page 57 • The participant must be informed that their personal study -related data will be used 
by [CONTACT_14342]. The level of disclosure 
must also b e explained to the participant  who will be required  to give consent for 
their data to be used as described in the informed consent . 
• The participant must be informed that their medical records may be examined by 
[CONTACT_13162] , by [CONTACT_6667]/IEC members,  and by [CONTACT_9326].  
• The contract between the Sponsor  or designee and the study sites may specif y 
responsibilities of the parties related to data protection, including handling of data 
security breache s and respective communication and cooperation of the parties.  
• Information technology systems used to collect, process, and store study -related data 
are secured by [CONTACT_14343], alteration, or unauthorized disclosure or 
access.  
10.1.6.  Committees Structure   
[IP_ADDRESS].  Internal Safety Team   
An IST will be formed to review primary and cumulative blinded and unblinded safety data on a 
regular basis.  
[IP_ADDRESS].  Cardiac Event Adjudication Committee   
An independent CEAC comprised of medically qualified personnel, including cardiologists, will 
review all reported cases of myocarditis, pericarditis, and myopericarditis to determine if they 
meet CDC criteria for “probable” or “confirmed” events ( Gargano et al 2021 ). Any cases that the 
CEAC assesses as representing probable or confirmed cases of myocarditis, pericarditis, or 
myopericarditis will be referred to the Sponsor, who will th en determine if additional action is 
needed. The CEAC operates under the rules of an approved charter . Details regarding the CEAC 
composition, responsibilities, procedures, and frequency of data review are defined in the 
charter.  
10.1.7.  Dissemination of Clinical Study Data   
ModernaTX, Inc. shares information about clinical studies and results on publicly accessible 
websites, based on international and local legal and regulatory requiremen ts, and other clinical 
study disclosure commitments established by [CONTACT_13174]. These 
websites include clinicaltrials.gov, EU clinicaltrialregister (eu.ctr), etc., as well as some national 
registries.  
10.1.8.  Data Quality Assurance   
• All participant data relating to the study will be recorded on printed or eCRFs unless 
transmitted to the Sponsor  or designee electronically (eg, laboratory data). The 
ModernaTX, Inc.  
mRNA -[ADDRESS_13627] by 
[CONTACT_1189].  
• Guidance on completion of CRFs will be provided in eCRF Completion Guidelines . 
• The Investigator  must permit study -related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections and provide direct access to source documents.  
• QTLs  will be predefined to identify systematic issues that can impact participant 
safety and/or reliability of study results. These predefined paramete rs will be 
monitored during the study, and important deviations from the QTLs and remedial 
actions taken will be summarized in the clinical study report.  
• Monitoring details describing strategy, including definition of study critical data 
items and processe s (eg, risk -based initiatives in operations and quality such as risk 
management and mitigation strategies and analytical risk -based monitoring), 
methods, responsibilities, and requirements, including handling of noncompliance 
issues and monitoring techniqu es (central, remote, or on site monitoring) are provided 
in the monitoring plan.  
• The Sponsor  or designee is responsible for the data management of this study , 
including quality checking of the data.  
• The Sponsor  assumes accountability for actions delegated t o other individuals (eg, 
contract research organizations).  
• Records and documents, including signed ICFs, pertaining to the conduct of this 
study must be retained by [CONTACT_14344] [ADDRESS_13628] article for inve stigation  unless local regulations or institutional policies require a 
longer retention period. No records may be destroyed during the retention period 
without the written approval of th e Sponsor . No records may be transferred to another 
location or party without written notification to the Sponsor . 
10.1.9.  Source Documents   
• Source documents provide evidence for the exis tence of the participant and 
substantiate the integrity of the data collected. Source documents are filed at the 
Investigator ’s site.  
• Data reported on the CRF or entered in the eCRF that are transcribed from source 
documents must be consistent with the sou rce documents or the discrepancies must be 
explained. The Investigator  may need to request previous medical records or transfer 
records, depending on the study. Also, current medical records must be available.  
• Definition of what constitutes source data and  its origin can be found in the source 
data declaration . 
• The Investigator  must maintain accurate documentation (source data) that supports 
the information entered in the CRF.  
ModernaTX, Inc.  
mRNA -1345 -P304  Protocol  mRNA -1345  
Confidential  Page 59 • The Sponsor  or designee will perform monitoring to confirm that data entered into the 
CRF by [CONTACT_1191], complete, and verifiable from source 
documents; that the safety and rights of participants are being protected; and that the 
study is being conducted in accordance with the currently approved protocol and any 
other study agreements, ICH GCP, and all applicable regulatory requirements.  
10.1.10.  Study and Site Start and Closure   
First Act of Recruitment  
The study start date is the date on which the clinical study will be open for recruitment of 
participants.  
The first act of recruitment is the first sit e open  and will be the study start date.  
Study/Site Termination  
The Sponsor  or designee reserves the right to close the study site or terminate the study at any 
time for any reason at the sole discretion of the Sponsor . Study sites will be closed upon stud y 
completion. A study site is considered closed when all required documents and study supplies 
have been collected and a study  site closure visit has been performed.  
The Investigator  may initiate study  site closure at any time, provided there is reasonable  cause 
and sufficient notice is given in advance of the intended termination.  
Reasons for the early closure of a study site by [CONTACT_14345]:  
For study termination:  
• Discontinuation of further study intervention development . 
For site termination:  
• Failure of the Investigator  to comply with the protocol, the requirements of the 
IRB/IEC or local health authorities, the Sponsor ’s procedures, or GCP guidelines . 
• Inadequate or no recruitment (evaluated after  a reasonable amount of time) of 
participants by [CONTACT_737] . 
• Total number of participants included earlier than expected . 
If the study is prematurely terminated or suspended, the Sponsor  shall promptly inform the 
Investigator s, the IECs/IRBs, the reg ulatory authorities, and any contract research 
organization(s) used in the study of the reason for termination or suspension, as specified by [CONTACT_13179]. The Investigator  shall promptly inform the participant and 
should assure a ppropriate participant therapy and/or follow -up. 
10.1.11.  Publication Policy   
• The results of this study may be published or presented at scientific meetings. If this 
is foreseen, the Inves tigator  agrees to submit all manuscripts or abstracts to the 
Sponsor  before submission. This allows the Sponsor  to protect proprietary 
information and to provide comments.  
ModernaTX, Inc.  
mRNA -1345 -P304  Protocol  mRNA -1345  
Confidential  Page 60 • The Sponsor  will comply with the requirements for publication of study results. In 
accordance with standard editorial and ethical practice, the Sponsor  will generally 
support publication of multicenter studies only in their entirety and not as individual 
site data. In this case, a coordinating Investigator  [INVESTIGATOR_9231].  
• Authorship will be determined by [CONTACT_14346].  
ModernaTX, Inc.  
mRNA -1345 -P304  Protocol  mRNA -1345  
Confidential  Page 61 10.2. Appendix  2: AEs  and SAEs : Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting   
10.2.1.  Definition of AE   
AE Definition  
• An AE is any untoward medical occurrence in a clinical study participant, temporally 
associated with the use of study intervention, whether or not considered related to the 
study intervention.  
• NOTE: An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or dis ease (new or exacerbated) temporally 
associated with the use of study intervention.  
Definition of Unsolicited and Solicited AE  
• An unsolicited AE is an AE that was not solicited using a participant diary and that is 
communicated by a participant  who has signed the informed consent. Unsolicited 
AEs include SAEs and nonserious AEs.  
• Potential unsolicited AEs may be medically attended (ie, symptoms or illnesses 
requiring a hospi[INVESTIGATOR_059], emergency room visit, or visit to/by a healthcare 
provider). T he participants  will be instructed to contact [CONTACT_14347](s), as well as any events that, though not medically 
attended, are of participant  concern. Detailed information about reported unsolicited 
AEs wil l be collected by [CONTACT_14348]’s 
records.  
• Unsolicited AEs that are not medically attended nor perceived as a concern by [CONTACT_14349].  
• Solicited AEs are predefined local (at the injection site ) and systemic events for 
which the participant is specifically questioned, and which are noted by [CONTACT_14350].  
Events Meeting the A E Definition  
• Any abnormal safety assessments (eg, vital signs measurements), including those that 
worsen from baseline, considered clinically significant in the medical and scientific 
judgment of the Investigator  (ie, not related to progression of underlyi ng disease , or 
more severe than expected for the participant’s condition ). 
• Exacerbation of a chronic or intermittent pre -existing condition including either an 
increase in frequency and/or intensity of the condition . 
• New condition detected or diagnosed after study intervention administration even 
though it may have been present before the start of the study . 
• Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction . 
ModernaTX, Inc.  
mRNA -1345 -P304  Protocol  mRNA -1345  
Confidential  Page 62 • Signs, symptoms, or the clinical sequelae of a suspected overdose of  either study 
intervention or a concomitant medication. Overdose per se will not be reported as an 
AE/SAE unless it is an intentional overdose taken with possible suicidal/self -harming 
intent. Such overdoses should be reported regardless of sequelae.  
Event s not Meeting the AE Definition  
• Any abnormal findings or other abnormal safety assessments that are associated with 
the underlying disease, unless judged by [CONTACT_14351]’s condition . 
• The disease/disor der being studied or expected progression, signs, or symptoms of the 
disease/disorder being studied, unless more severe than expected for the participant’s 
condition . 
• Medical or surgical procedure (eg, endoscopy, appendectomy): the condition that 
leads to the procedure is the AE . 
• Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]) . 
• Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present 
or detected at the start o f the study that do not worsen . 
10.2.2.  Definition of SAE   
An SAE is defined as any untoward medical occurrence that, at any dose, meets one or more of 
the criteria listed:  
a. Results in dea th 
b. Is life -threatening  
The term life-threatening  in the definition of serious  refers to an event in which the participant 
was at risk of death at the time of the event. It does not refer to an event, which hypothetically 
might have caused death, if it were  more severe.  
c. Requires inpatient hospi[INVESTIGATOR_1081]  
• In general, hospi[INVESTIGATOR_12994] (usually 
involving at least an overnight stay) at the hospi[INVESTIGATOR_1083]/or treatment that would not have been appropriate in the physician’s 
office or outpatient setting. Complications that occur during hospi[INVESTIGATOR_1084]. 
If a complication prolongs hospi[INVESTIGATOR_9236], th e 
event is serious. When in doubt as to whether hospi[INVESTIGATOR_14275], the AE should be considered serious.  
• Hospi[INVESTIGATOR_5187] a pre -existing condition that did not worsen 
from baseline is not considered an AE.  
d. Results in persistent or significant disability/incapacity  
• The term disability means a substantial disruption of a person’s ability to conduct 
normal life functions.  
ModernaTX, Inc.  
mRNA -1345 -P304  Protocol  mRNA -1345  
Confidential  Page 63 • This definition is not intended to include experiences of relatively minor medical 
signifi cance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, 
and accidental trauma (eg, sprained ankle) that may interfere with or prevent 
everyday life functions but do not constitute a substantial disruption.  
e. Is a congenital anomaly/birth  defect  
f. Other situations:  
• Medical or scientific judgment should be exercised by [CONTACT_14352] -threatening or resu lt in death or 
hospi[INVESTIGATOR_14276]. These 
events should usually be considered serious.  
− Examples of such event s include invasive or malignant cancers, intensive 
treatment in an emergency room or at home for allergic bronchospasm, blood 
dyscrasias, convulsions not resulting in hospi[INVESTIGATOR_059], or development of 
intervention dependency or intervention abuse.  
10.2.3.  Definit ion of MAAE   
A MAAE is an AE that leads to an USV  to a healthcare practitioner. This would include visits to 
a study site for unscheduled assessments not required per protocol (e.g., rash assessment, 
abnormal laboratory follow -up) and visits to healthcare practitioners external to the study site 
(e.g., emergency room, urgent care, primary care physician).  
10.2.4.  Definition of AESI   
An AESI is an AE (serious or nonserious) of scientific and medical concern specific to the 
Sponsor’s product or program, for which ongoing monitoring and immediate notification by [CONTACT_14353]. Such event s may require further investigation to 
characterize and understand them.  
The AESIs defined for this protocol can be f ound in Section  10.3.1 . 
10.2.5.  Recording and Follow -Up of AE and/or SAE   
AE and SAE Recording  
• When an AE/SAE occurs, it is the responsibility of the Investigator  to review all 
documentation (eg, hospi[INVESTIGATOR_1088], laboratory r eports, and diagnostics 
reports) related to the event.  
• The Investigator  will then record all relevant AE/SAE information.  
• It is not acceptable for the Investigator  to send photocopi[INVESTIGATOR_10914]’s 
medical records to the Sponsor  or designee  in lieu of completion of the eCRF  
/required form.  
• There may be instances when copi[INVESTIGATOR_14277] . In this case, all participant identifiers, with the 
ModernaTX, Inc.  
mRNA -1345 -P304  Protocol  mRNA -1345  
Confidential  Page 64 exception of the participant number, will be red acted on the copi[INVESTIGATOR_14278] . 
• The Investigator  will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not 
the individual signs/symptoms) will be documented as the AE/SAE.  
Assessment of Intensity  
The Investigator  will make an assessment of intensity for each AE and SAE reported during the 
study and assign it to one of the following categories:  
• Mild  
A type of AE  that is usually transient and may require only minimal treatment or 
therapeutic intervention. The event does not generally interfere with usual activities 
of daily living.  
• Moderate  
A type of AE that is usually alleviated with additional specific therapeut ic 
intervention. The event interferes with usual activities of daily living, causing 
discomfort but poses no significant or permanent risk of harm to the research 
participant.  
• Severe  
A type of AE that interrupts usual activities of daily living, or signifi cantly affects 
clinical status, or may require intensive therapeutic intervention.  
The Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive 
Vaccine Clinical  Trials ( DHHS  2007 ) will be used to categorize local and systemic 
reactogenicity events ( solicited ARs ), clinical laboratory test results, and vital sign measurements 
observed during this study. The intensity grading scale used in this study is presented in Table  7. 
Table  7: Adult and Adolescent Solicited Adverse Reactions and Grades  
Reaction  Grade  0 
(None)  Grade  1 
(Mild)  Grade  2 
(Moderate)  Grade  3 
(Severe ) Grade  4 
(Life -threatening)  
Local  
Injection site pain  None  No interference 
with activity  Some 
interference 
with activity  Prevents 
daily activity  Requires emergency 
room visit or 
hospi[INVESTIGATOR_14279] (redness)  <25 mm/ 
<2.5 cm 25-50 mm/ 
2.5-5 cm  51-100 mm/ 
5.1-10 cm  >100  mm/ 
>10 cm Necrosis or 
exfoliative 
dermatitis  
Injection site 
swelling/induration 
(hardness)  <25 mm/ 
<2.5 cm  25-50 mm/ 
2.5-5 cm  51-100 mm/ 
5.1-10 cm >100  mm/ 
>10 cm Necrosis  
ModernaTX, Inc.  
mRNA -1345 -P304  Protocol  mRNA -1345  
Confidential  Page 65 Reaction  Grade  0 
(None)  Grade  1 
(Mild)  Grade  2 
(Moderate)  Grade  3 
(Severe ) Grade  4 
(Life -threatening)  
Axillary 
(underarm) 
swelling or 
tenderness  
ipsilateral to the 
side of injection  None  No interference 
with activity  Some 
interference 
with activity  Prevents 
daily activity  Requires emergency 
room visit or 
hospi[INVESTIGATOR_14280]  
(muscle aches all 
over body)  None  No interference 
with activity  Some 
interference 
with activity  Prevents 
daily activity  Requires emergency 
room visit or 
hospi[INVESTIGATOR_14281]  
(joint aches in 
several joints)  None  No interference 
with activity  Some 
interference 
with activity  Prevents 
daily activity  Requires emergency 
room visit or 
hospi[INVESTIGATOR_14282]/vomiting  None  No interference 
with activity or 
1-2 epi[INVESTIGATOR_1841]/ 
24 hours  Some 
interference 
with activity or 
>2 epi[INVESTIGATOR_1865] s/24
hours  Prevents 
daily 
activity, 
requires 
outpatient 
intravenous 
hydration  Requires emergency 
room visit or 
hospi[INVESTIGATOR_14283] (oral)  <38.0°C  
<100.4°F  38.0-38.4°C  
100.4 -101.1°F  38.5-38.9°C  
101.2 -102.0°F  39.0-40.0°C  
102.1 -
104.0°F  >40.0°C  
>104.0°F  
Note : Events listed above but starting >[ADDRESS_13629] study  intervention dosing will be recorded in the eCRF . Causality 
for each event will be determined per assessment by [CONTACT_737] . 
ModernaTX, Inc.  
mRNA -1345 -P304  Protocol  mRNA -1345  
Confidential  Page 66 Modified from the Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive 
Vaccine Clinical Trials ( DHHS  2007 ). 
Assessment of Causality  
• The Investigator  is obligated to assess the relationship between study intervention and 
each occurrence of each AE/SAE. The Investigator  will use clinical judgment to 
determine the relationship.  
• Not related: There is not a reasonable possibility of a relationship to the study 
intervention. Participant did not receive the study intervention OR temporal sequence 
of the AE onset relative to a dministration of the study intervention is not reasonable 
OR the AE is more likely explained by [CONTACT_14354].  
• Related: There is a reasonable possibility of a relationship to the study intervention. 
There is evidence of exposure  to the study intervention. The temporal sequence of the 
AE onset relative to the administration of the study intervention is reasonable. The 
AE is more likely explained by [CONTACT_14355].  
• For causality assessment, the Investi gator  will also consult the IB and/or product 
information, for marketed products.  
• The Investigator  must review and provide an assessment of causality for each 
AE/SAE and document this in the medical notes . There may be situations in which an 
SAE has occurr ed and the Investigator  has minimal information to include in the 
initial report to the Sponsor  or designee . However, it is very important that the 
Investigator  always make an assessment of causality for every event before the initial 
transmission of the S AE data to the Sponsor  or designee . 
• The Investigator  may change their opi[INVESTIGATOR_9242] -up 
information and send an SAE follow -up report with the updated causality assessment.  
• The causality assessment is one of the criteria used when d etermining regulatory 
reporting requirements.  
Follow -up of AEs and SAEs  
• The Investigator  is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by [CONTACT_14356]/or causality of the AE or SAE as fully 
as possible. This may include additional laboratory tests or investigations, 
histopathological examinations, or consultation with other health care professionals.  
• If a participant dies during  participation in the study or during a recognized follow -up 
period, the Investigator  will provide the Sponsor or designee with a copy of any 
postmortem findings including histopathology.  
• New or updated information will be recorded in the originally submit ted documents.  
• The Investigator  will submit any updated SAE data to the Sponsor or designee  within 
24 hours of receipt of the information.  
ModernaTX, Inc.  
mRNA -1345 -P304  Protocol  mRNA -1345  
Confidential  Page 67 10.2.6.  Reporting of SAEs   
SAE Reporting to the Sponsor or Designee  via an EDC  Tool  
• The primary mechanism for reporting an SAE to the Sponsor or designee  will be the 
EDC  tool. 
• If the electronic system is unavailable, then the site will use the paper SAE data 
collection tool (see next section) to rep ort the event within 24 hours.  
• The site will enter the SAE data into the electronic system as soon as it becomes 
available.  
• After the study is completed at a given site, the EDC  tool will be taken offline to 
prevent the entry of new data or changes to exis ting data.  
• If a site receives a report of a new SAE from a study participant or receives updated 
data on a previously reported SAE after the EDC  tool has been taken offline, then the 
site can report this information on a paper SAE form (see next section) . 
SAE Reporting to the Sponsor or Designee  via Paper Data Collection Tool  
• If EDC is unavailable and the site needs to use a paper form to report SAEs , email 
transmission of the SAE paper data collection tool may be used to transmit this 
information to the Sponsor . 
• Initial notification via email does not replace the need for the Investigator  to complete 
and sign the electronic SAE data collection tool within the designated reporting 
timeframes.  
• SAE report s should be emailed to  . 
10.3. Appendix  3: Adverse Events of Special Interest   
10.3.1.  AESIs   
Investigators should report all events that fall into the categories presented in  Table  [ADDRESS_13630] in vaccine safety surveillance as per the Brighton Collaboration and safety 
platform for emergency v accines ( Brighton Collaboration 2019 ). 
Table  8: Adverse Events of Special Interes t  
Medical Concept  Additional Notes  
Thrombocytopenia  • Platelet counts < 125×109 cells per liter . 
• Including but not limited to immune thrombocytopenia, 
platelet production decreased, thrombocytopenia, 
thrombocytopenic purpura, thrombotic thrombocytopenic 
purpura, or HELLP syndrome . 
New onset of or worsening of 
neurologic diseases  Neurologic diseases include the following:  
• Guillain -Barré Syndrome . 
• Acute disseminated encephalomyelitis . 
[COMPANY_003]
ModernaTX, Inc.  
mRNA -1345 -P304  Protocol  mRNA -1345  
Confidential  Page 68 Medical Concept  Additional Notes  
• Idiopathic peripheral facial nerve palsy (Bell’s palsy) . 
• Seizures including but not limited to febrile seizures 
and/or generalized  seizures/convulsions . 
Anaphylaxis  • Anaphylaxis as defined per protocol Section  [IP_ADDRESS] . 
• Follow the reporting procedures in protocol Section  8.4. 
Myocarditis/Pericarditis  • Myocarditis . 
• Pericarditis . 
• Myopericarditis . 
Abbreviation: HELLP  = hemolysis, elevated liver enzymes, and low platelet count . 
10.4. Appendix  4: CDC Working Case Definitions of Pericarditis, 
Myocarditis, and Myopericarditis  After Receipt of COVID -19 
mRNA Vaccines   
The CDC Working Case Definitions of probable and confirmed myocarditis, peri carditis, and 
myopericarditis ( Gargano et al 2021 ) are provided in Table  9 as guidance.  
Table  9: Case Definitions of Probably and Confirmed Myocarditis, Pericarditis, and 
Myopericarditis  After Receipt of COVID -19 mRNA Vaccines  
Condition  Definition  
Acute 
myocarditis  Probable case  Confirmed case  
Presence of ≥1 new or worsening of 
the following clinical symptoms:*  
• Chest pain, pressure, or 
discomfort.  
• Dyspnea, shortness of breath, or 
pain with breathing.  
• Palpi[INVESTIGATOR_814].  
• Syncope.  Presence of ≥1 new or worsening of the 
following clinical symptoms:*  
• Chest pain, pressure, or discomfort.  
• Dyspnea, shortness of breath, or pain 
with breathing.  
• Palpi[INVESTIGATOR_814].  
• Syncope.  
OR, infants and children aged 
<[ADDRESS_13631] ≥2 of 
the following symptoms:  
• Irritability.  
• Vomiting.  
• Poor feeding.  
• Tachypnea.  
• Lethargy.  OR, infants and children aged <[ADDRESS_13632] ≥2 of the following 
symptoms:  
• Irritability.  
• Vomiting.  
• Poor feeding.  
• Tachypnea.  
• Lethargy.  
ModernaTX, Inc.  
mRNA -1345 -P304  Protocol  mRNA -1345  
Confidential  Page 69 Condition  Definition  
AND  
≥1 new finding of  
• Troponin level above upper 
limit of normal (any type of 
troponin).  
• Abnormal ECG or EKG or 
rhythm monitoring findings 
consistent with myocarditis§. 
• Abnormal cardiac function or 
wall motion abnormalities on 
echocardiogram.  
• cMRI findings consistent with 
myocarditis§§. AND  
≥1 new finding of  
• Histopathologic confirmation of 
myocarditis†. 
• cMRI findings consistent with 
myocarditis§§ in the presence of troponin 
level above upper limit of normal (any 
type of troponin).  
AND  
• No other identifiable cause of 
the symptoms and findings.  AND  
• No other identifiable cause of the 
symptoms and findings.  
Acute 
pericarditis**  Presence of ≥2 new or  worsening of the following clinical features:  
• Acute chest pain .†† 
• Pericardial rub on exam.  
• New ST -elevation or PR -depression on EKG.  
• New or worsening pericardial effusion on echocardiogram or MRI.  
Myopericarditis  This term may be used for participants wh o meet criteria for both myocarditis and 
pericarditis.  
Abbreviations: cMRI  = cardiac magnetic resonance imaging; ECG or EKG  = electrocardiogram; MRI  = magnetic 
resonance imaging . 
* Persons who lack the listed symptoms but who meet other criteria may be cl assified as subclinical myocarditis 
(probable or confirmed).  
† Using the Dallas criteria ( Aretz et al 1987 ). Autopsy cases may be classified as confirmed clinical myocarditis on 
the basis of meeting histopathologic criteria if no o ther identifiable cause.  
§ To meet the ECG or rhythm monitoring criterion, a probable case must include at least one of 1) ST -segment or 
T-wave abnormalities; 2) Paroxysmal or sustained atrial, supraventricular, or ventricular arrhythmias; or 3) AV 
nodal c onduction delays or intraventricular conduction defects.  
§§ Using either the original or the revised Lake Louise criteria. 
https://www.sciencedirect.com/science/article/pii/S0735109718388430?via%3Dihubexternal icon . 
** https://academic.oup.com/eurheartj/article/36/42/2921/2293375external icon.  
†† Typi[INVESTIGATOR_14284], deep inspi[INVESTIGATOR_1516], or cough, and relieved by [CONTACT_14357], although other types of chest pain might occur.  
Reference: ( Gargano et al 2021 ). 
ModernaTX, Inc.  
mRNA -1345 -P304  Protocol  mRNA -1345  
Confidential  Page 70 11. REFERENCES   
Aretz HT, Billingham ME, Edwards WD, Factor SM, Fallon JT, Fenoglio JJ Jr., et al. 
Myocarditis. A histopath ologic definition and classification. Am J Cardiovasc Pathol. 
1987;1(1):3 -14. 
Bartoszko J, Loeb M. The burden of influenza in older adults: Meeting the challenge. Aging Clin 
Exp Res. 2021;33(3):711 -7. 
Brighton Collaboration [homepage on the Internet]. The Task Force for Global Health. 2019 
May 09. Safety Platform for Emergency Vaccines (SPEAC) [updated 2019 May 09; cited 2023 
Jun 20]. Available from: https://brightoncollaboration.us/speac/ . 
ClinicalTrials.gov [Internet], Bethesda (MD): National Library of M edicine (US). Identifier 
[STUDY_ID_REMOVED] . A Study of mRNA -1345 vaccine targeting respi[INVESTIGATOR_4345] (RSV) in 
adults ≥50 years of age (RSVictory). (2022 Nov 15; cited 2023 Jul 17). Retrieved from: 
https://clinicaltrials .gov/study/[STUDY_ID_REMOVED].  
ClinicalTrials.gov [Internet], Bethesda (MD): National Library of Medicine (US). Identifier 
[STUDY_ID_REMOVED] . A study to evaluate the safety and efficacy of mRNA -1345 vaccine targeting 
respi[INVESTIGATOR_4345] (RSV) in adults ≥60 tears of age. (2023 Dec 31 ; cited 2023 Jul 17). 
Retrieved from: https://clinicaltrials .gov/study/ [STUDY_ID_REMOVED] . 
ClinicalTrials.gov [Internet], Bethesda (MD): National Library of Medicine (US). Identifier 
[STUDY_ID_REMOVED] . A study of modified mRNA vaccines in healthy adults . (2024 Mar 25 ; cited 2023 
Jul 17). Retrieved from: https://clinicaltrials .gov/study/ [STUDY_ID_REMOVED] . 
ClinicalTrials.gov [Internet], Bethesda (MD): National Library of Medicine (US). Identifier 
[STUDY_ID_REMOVED] . A safety, reactogenicity, and immunogenicity study of mRNA -1045 (influe nza 
and respi[INVESTIGATOR_4345] [RSV]) or mRNA -1230 (influenza, RSV, and severe acute 
respi[INVESTIGATOR_6507] 2 [SARS -CoV -2]) vaccine in adults 50 to 75 years old . (2024 
Mar 15 (estimated) ; cited 2023 Jul 17). Retrieved from: 
https://clinicalt rials.gov/study/ [STUDY_ID_REMOVED] . 
ClinicalTrials.gov [Internet], Bethesda (MD): National Library of Medicine (US). Identifier 
[STUDY_ID_REMOVED] . A dose escalation study to evaluate safety, reactogenicity, and immunogenicity 
of mRNA -1345 in healthy adults and in children who are respi[INVESTIGATOR_4345] (RSV) -
seropositive . (2023 Sep 30 (estimated) ; cited 2023 Jul 17). Retrieved from: 
https://clini caltrials .gov/study /[STUDY_ID_REMOVED] . 
Crank MC, Ruckwardt TJ, Chen M, Morabito KM, Phung E, Costner PJ, et al; VRC 317 Study 
Team. A proof of concept for structure -based vaccine design targeting RSV in humans. Science. 
2019;365(6452):505 -9. 
Czaja CA, Miller L, Alden N, Wald HL, Cummings CN, Rolfes MA, et al. Age -related 
differences in hospi[INVESTIGATOR_14285], clinical presentation, and outcomes among older adults 
hospi[INVESTIGATOR_14286] -U.S. Influenza Hospi[INVESTIGATOR_14287] (FluSurv -NET). 
Open Fo rum Infect Dis. 2019;6(7):ofz225.  
ModernaTX, Inc.  
mRNA -1345 -P304  Protocol  mRNA -1345  
Confidential  Page 71 Department of Health and Human Services (DHHS), Food and Drug Administration, Center for 
Biologics Evaluation and Research (US). Guidance for industry: Toxicity grading scale for 
healthy adult and adolescent volunteers enr olled in preventive vaccine clinical trials. September 
2007 [cited 2023 Jun 20 ]. Available from: 
https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInfor
mation/Guidances/Vaccines/ucm091977.pdf.  
Falsey AR, Hennessey PA, Formica  MA, Cox C, Walsh EE. Respi[INVESTIGATOR_14288] -risk adults. N Engl J Med. 2005;352(17):1749 -59. 
Gargano JW, Wallace M, Hadler SC, Langley G, Su JR, Oster ME, et al. Use of mRNA COVID 
19 vaccine after reports of myocarditis among vaccine recipi[INVESTIGATOR_840]: Update from the Advisory 
Committee on Immunization Practices – [LOCATION_002], June 2021. MMWR Morb Mortal Wkly 
Rep. 2021;70(27):[ADDRESS_13633] infections in 195 countries: A systematic 
analysis for the Global Burden of Disease Study 2015. Lancet Infect Dis. 2017;17(11):1133 -61. 
Graham BS. Immunological goals for respi[INVESTIGATOR_14289]. Curr 
Opin Immunol. 2019;59: 57-64. 
Kurzweil V, Tang R, Galinski M, Wang K, Zuo F, Cherukuri A, et al. Translational sciences 
approach to RSV vaccine development. Expert Rev Vaccines. 2013;12(9):[ADDRESS_13634] Dis. 2002;185(5):682 -5. 
McLellan JS, Chen M, Joyce MG, Sastry M, Stewart -Jones GB, Yang Y, et al. Structure -based 
design of a fusion glycoprotein vaccine for respi[INVESTIGATOR_4345]. Science. 
2013;342(6158): 592-8. 
Monto AS. Reflections on the global influenza surveillance and response system (GISRS) at 65 
years: An expanding framework for influenza detection, prevention, and control. Influenza Other 
Respir Viruses. 2018;12(1):10 -2. 
Ngwuta JO, Chen M, Modjarrad K, Joyce MG, Kanekiyo M, Kumar A, et al. Prefusion F -
specific antibodies determine the magnitude of RSV neutralizing activity in human sera. Sci 
Transl Med. 2015;7(309):309ra162.  
Riedel  S, Hobden JA, Miller S, Morse SA, Mietzner TA, Detrick B, et al. Orthomyxoviruses 
(Influenza Viruses) . In: Jawetz, Melnick & Adelberg’s Medical Microbiology . 28th ed. New 
York: McGraw -Hill Education; 2019. p. 581 -94. 
Rüggeberg JU, Gold MS, Bayas JM, Blum MD, Bonhoeffer J, Friedlander S, et al; Brighton 
Collaboration Anaphylaxis Working Group. Anaphylaxis: case definition and guidelines for data 
collection, analysis, and presentation of immunization safety data. Vaccine. 2007;25(31):5675 -
84. 
[COMPANY_011] Pasteur . Fluzone HD Quadrivalent [package insert ]. U.S. Food and Drug Administration 
website  https://www.fda.gov/media/139731/download. Revised January  2023.  Accessed  
13 Jul 2023 . 
ModernaTX, Inc.  
mRNA -1345 -P304  Protocol  mRNA -1345  
Confidential  Page 72 Shi T, Denouel A, Tietjen AK, Campbell I, Moran E, Li X, et al. Global disease burden estimates 
of respi[INVESTIGATOR_4345] -associated acute respi[INVESTIGATOR_14290] 2015: A 
systematic review and meta -analysis . J Infect Dis. 2020;222(Suppl 7):S577 -83. 
Walsh EE, Peterson DR, Kalkanoglu AE, Lee FEH, Falsey AR . Viral shedding and immune 
responses to respi[INVESTIGATOR_14291]. J Infect Dis. 2013;207(9):1424 -
32. 
World Health Organization (WHO) [homepage on the Internet]. Influenza (seasonal): Ask the 
expert: influenza Q&A. [updated 12 January 2023 ; cited 2023 Jun 26]. Available from:  
https://www.who.int/news -room/fact -sheets/detail/influenza -(seasonal) . 
Zent O, Arras -Reiter C, Broeker M, Hennig R. Immediate allergic reactions after vaccinations -a 
post-marketing surveilla nce review. Eur J Pediatr. 2002;161(1):21 -5. 
Signature [CONTACT_11032]-CLIN-011142 v1.0
Signature [CONTACT_11032]-CLIN-011142 v1.02nd Approval (Moderna)
21-Jul-2023 13:11:01 GMT[PHONE_006]
[COMPANY_003]